efile GRAPHIC print - DO NOT PROCESS | As Filed Data - | DLN: 93493137026420

Form **990**

Department of the Treasury
Internal Revenue Service

Return of Organization Exempt From Income Tax

Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except black lung benefit trust or private foundation)

▶ The organization may have to use a copy of this return to satisfy state reporting requirements

OMB No 1545-0047

2008

Open to Public Inspection

A For the 2008 calendar year, or tax year beginning 07-01-2008 and ending 06-30-2009

B Check if applicable	Please use IRS label or print or type. See Specific Instructions.	C Name of organization		D Employer identification number
☐ Address change		THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE		75-3065445
☐ Name change		Doing Business As		E Telephone number (602) 343-8423
☐ Initial return		Number and street (or P O box if mail is not delivered to street address) 445 N 5TH STREET SUITE 600	Room/suite	G Gross receipts $ 59,109,975
☐ Termination				
☐ Amended return		City or town, state or country, and ZIP + 4 PHOENIX, AZ 85004		
☐ Application pending				

F Name and address of Principal Officer
JEFFREY TRENT PHD
445 N FIFTH STREET 600
PHOENIX,AZ 85004

H(a) Is this a group return for affiliates? ☐ Yes ☑ No

H(b) Are all affiliates included? ☐ Yes ☐ No
(If "No," attach a list See instructions)

H(c) Group Exemption Number ▶

I Tax-exempt status ☑ 501(c) (3) ◀ (insert no) ☐ 4947(a)(1) or ☐ 527

J **Web site:** ▶ www tgen org

K Type of organization ☑ Corporation ☐ trust ☐ association ☐ other ▶ | L Year of Formation 2002 | M State of legal domicile AZ

Part I Summary

Activities & Governance

1 Briefly describe the organization's mission or most significant activities
SEE SCHEDULE O

2 Check this box ☐ if the organization discontinued its operations or disposed of more than 25% of its assets

3	Number of voting members of the governing body (Part VI, line 1a)	3	24
4	Number of independent voting members of the governing body (Part VI, line 1b)	4	22
5	Total number of employees (Part V, line 2a)	5	405
6	Total number of volunteers (estimate if necessary)	6	23
7a	Total gross unrelated business revenue from Part VIII, line 12, column (C)	7a	612,002
b	Net unrelated business taxable income from Form 990-T, line 34	7b	64,317

			Prior Year	Current Year
Revenue	8	Contributions and grants (Part VIII, line 1h)	48,715,607	40,267,050
	9	Program service revenue (Part VIII, line 2g)	18,650,112	18,077,572
	10	Investment income (Part VIII, column (A), lines 3, 4, and 7d)	4,605,406	493,546
	11	Other revenue (Part VIII, column (A), lines 5, 6d, 8c, 9c, 10c, and 11e)	204,892	271,807
	12	Total revenue—add lines 8 through 11 (must equal Part VIII, column (A), line 12)	72,176,017	59,109,975
Expenses	13	Grants and similar amounts paid (Part IX, column (A), lines 1–3)	0	0
	14	Benefits paid to or for members (Part IX, column (A), line 4)	0	0
	15	Salaries, other compensation, employee benefits (Part IX, column (A), lines 5–10)	24,055,529	25,630,754
	16a	Professional fundraising fees (Part IX, column (A), line 11e)	0	0
	b	(Total fundraising expenses, Part IX, column (D), line 25 0)		
	17	Other expenses (Part IX, column (A), lines 11a–11d, 11f–24f)	34,194,014	31,179,506
	18	Total expenses—add lines 13–17 (must equal Part IX, line 25, column (A))	58,249,543	56,810,260
	19	Revenue less expenses Subtract line 18 from line 12	13,926,474	2,299,715
Net Assets or Fund Balances			**Beginning of Year**	**End of Year**
	20	Total assets (Part X, line 16)	37,180,477	42,716,831
	21	Total liabilities (Part X, line 26)	18,085,079	18,951,477
	22	Net assets or fund balances Subtract line 21 from line 20	19,095,398	23,765,354

Part II Signature Block

Under penalties of perjury, I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete Declaration of preparer (other than officer) is based on all information of which preparer has any knowledge

Please Sign Here

Signature of officer | Date 2010-05-17

ELIZABETH MONTEMAYOR CFO
Type or print name and title

Paid Preparer's Use Only

Preparer's signature ▶	Date	Check if self-empolyed ▶ ☐	Preparer's PTIN (See Gen Inst)
Firm's name (or yours if self-employed), address, and ZIP + 4 ▶	ERNST & YOUNG US LLP TWO NORTH CENTRAL AVENUE STE 2300 PHOENIX, AZ 85004		EIN ▶ Phone no ▶ (602) 322-3000

May the IRS discuss this return with the preparer shown above? (See instructions) ☐ Yes ☐ No

Part III **Statement of Program Service Accomplishments** (See the instructions.)

1 Briefly describe the organization's mission

SEE SCHEDULE O

2 Did the organization undertake any significant program services during the year which were not listed on the prior Form 990 or 990-EZ? . . . . ☐ **Yes** ☑ **No**

If "Yes," describe these new services on Schedule O

3 Did the organization cease conducting or make significant changes in how it conducts any program services? . . . . ☐ **Yes** ☑ **No**

If "Yes," describe these changes on Schedule O

4 Describe the exempt purpose achievements for each of the organization's three largest program services by expenses Section 501(c)(3) and (4) organizations and 4947(a)(1) trusts are required to report the amount of grants and allocations to others, the total expenses, and revenue, if any, for each program service reported

4a (Code) (Expenses $ 4,232,943 including grants of $) (Revenue $ 5,647,174)

SEE SCHEDULE O

4b (Code) (Expenses $ 3,408,484 including grants of $) (Revenue $ 5,438,364)

SEE SCHEDULE O

4c (Code) (Expenses $ 3,521,718 including grants of $) (Revenue $ 3,974,787)

SEE SCHEDULE O

4d Other program services (Describe in Schedule O)

(Expenses $ 22,402,500 including grants of $) (Revenue $ 3,017,247)

4e Total program service expenses $ 33,565,645 *Must equal Part IX, Line 25, column (B).*

Part IV Checklist of Required Schedules

			Yes	No
1	Is the organization described in section 501(c)(3) or 4947(a)(1) (other than a private foundation)? *If "Yes," complete Schedule A*	1	Yes	
2	Is the organization required to complete Schedule B, Schedule of Contributors?	2	Yes	
3	Did the organization engage in direct or indirect political campaign activities on behalf of or in opposition to candidates for public office? *If "Yes," complete Schedule C, Part I*	3		No
4	Section 501(c)(3) organizations Did the organization engage in lobbying activities? *If "Yes," complete Schedule C, Part II*	4		No
5	Section 501(c)(4), 501(c)(5), and 501(c)(6) organizations Is the organization subject to the section 6033(e) notice and reporting requirement and proxy tax? *If "Yes," complete Schedule C, Part III*	5		
6	Did the organization maintain any donor advised funds or any accounts where donors have the right to provide advice on the distribution or investment of amounts in such funds or accounts? *If "Yes," complete Schedule D, Part I*	6		No
7	Did the organization receive or hold a conservation easement, including easements to preserve open space, the environment, historic land areas or historic structures? *If "Yes," complete Schedule D, Part II*	7		No
8	Did the organization maintain collections of works of art, historical treasures, or other similar assets? *If "Yes," complete Schedule D, Part III*	8		No
9	Did the organization report an amount in Part X, line 21, serve as a custodian for amounts not listed in Part X, or provide credit counseling, debt management, credit repair, or debt negotiation services? *If "Yes," complete Schedule D, Part IV*	9		No
10	Did the organization hold assets in term, permanent,or quasi-endowments? *If "Yes," complete Schedule D, Part V*	10	Yes	
11	Did the organization report an amount in Part X, lines 10, 12, 13, 15, or 25? *If "Yes," complete Schedule D, Parts VI, VII, VIII, IX, or X as applicable*	11	Yes	
12	Did the organization receive an audited financial statement for the year for which it is completing this return that was prepared in accordance with GAAP? *If "Yes," complete Schedule D, Parts XI, XII, and XIII*	12		No
13	Is the organization a school as described in section 170(b)(1)(A)(ii)? *If "Yes," complete Schedule E*	13		No
14a	Did the organization maintain an office, employees, or agents outside of the U S ?	14a		No
b	Did the organization have aggregate revenues or expenses of more than $10,000 from grantmaking, fundraising, business, and program service activities outside the U S ? *If "Yes," complete Schedule F, Part I*	14b	Yes	
15	Did the organization report on Part IX, column (A), line 3, more than $5,000 of grants or assistance to any organization or entity located outside the United States? *If "Yes," complete Schedule F, Part II*	15		No
16	Did the organization report on Part IX, column (A), line 3, more than $5,000 of aggregate grants or assistance to individuals located outside the United States? *If "Yes," complete Schedule F, Part III*	16		No
17	Did the organization report more than $15,000 on Part IX, column (A), line 11e? *If "Yes," complete Schedule G, Part I*	17		No
18	Did the organization report more than $15,000 total on Part VIII, lines 1c and 8a? *If "Yes," complete Schedule G, Part II*	18		No
19	Did the organization report more than $15,000 on Part VIII, line 9a? *If "Yes," complete Schedule G, Part III*	19		No
20	Did the organization operate one or more hospitals? *If "Yes," complete Schedule H*	20		No
21	Did the organization report more than $5,000 on Part IX, column (A), line 1? *If "Yes," complete Schedule I, Parts I and II*	21		No
22	Did the organization report more than $5,000 on Part IX, column (A), line 2? *If "Yes," complete Schedule I, Parts I and III*	22		No
23	Did the organization answer "Yes" to Part VII, Section A, questions 3, 4, or 5? *If "Yes," complete Schedule J*	23	Yes	
24a	Did the organization have a tax-exempt bond issue with an outstanding principal amount of more than $100,000 as of the last day of the year, that was issued after December 31, 2002? *If "Yes," answer questions 24b–24d and complete Schedule K. If "No," go to question 25*	24a		No
b	Did the organization invest any proceeds of tax-exempt bonds beyond a temporary period exception?	24b		
c	Did the organization maintain an escrow account other than a refunding escrow at any time during the year to defease any tax-exempt bonds?	24c		
d	Did the organization act as an "on behalf of" issuer for bonds outstanding at any time during the year?	24d		
25a	Section 501(c)(3) and 501(c)(4) organizations Did the organization engage in an excess benefit transaction with a disqualified person during the year? *If "Yes," complete Schedule L, Part I*	25a		No
b	Did the organization become aware that it had engaged in an excess benefit transaction with a disqualified person from a prior year? *If "Yes," complete Schedule L, Part I*	25b		No
26	Was a loan to or by a current or former officer, director, trustee, key employee, highly compensated employee, or disqualified person outstanding as of the end of the organization's tax year? *If "Yes," complete Schedule L, Part II*	26		No
27	Did the organization provide a grant or other assistance to an officer, director, trustee, key employee, or substantial contributor, or to a person related to such an individual? *If "Yes," complete Schedule L, Part III*	27		No

Part IV **Checklist of Required Schedules** *(Continued)*

			Yes	No
28	During the tax year, did any person who is a current or former officer, director, trustee, or key employee			
a	Have a direct business relationship with the organization (other than as an officer, director, trustee, or employee), or an indirect business relationship through ownership of more than 35% in another entity (individually or collectively with other person(s) listed in Part VII, Section A)? *If "Yes," complete Schedule L, Part IV*	**28a**		No
b	Have a family member who had a direct or indirect business relationship with the organization? *If "Yes," complete Schedule L, Part IV*	**28b**		No
c	Serve as an officer, director, trustee, key employee, partner, or member of an entity (or a shareholder of a professional corporation) doing business with the organization? *If "Yes," complete Schedule L, Part IV*	**28c**	Yes	
29	Did the organization receive more than $25,000 in non-cash contributions? *If "Yes," complete Schedule M*	**29**		No
30	Did the organization receive contributions of art, historical treasures, or other similar assets, or qualified conservation contributions? *If "Yes," complete Schedule M*	**30**		No
31	Did the organization liquidate, terminate, or dissolve and cease operations? *If "Yes," complete Schedule N, Part I*	**31**		No
32	Did the organization sell, exchange, dispose of, or transfer more than 25% of its net assets? *If "Yes," complete Schedule N, Part II*	**32**		No
33	Did the organization own 100% of an entity disregarded as separate from the organization under Regulations section 301 7701-2 and 301 7701-3? *If "Yes," complete Schedule R, Part I*	**33**		No
34	Was the organization related to any tax-exempt or taxable entity? *If "Yes," complete Schedule R, Parts II, III, IV, and V, line 1*	**34**	Yes	
35	Is any related organization a controlled entity within the meaning of section 512(b)(13)? *If "Yes," complete Schedule R, Part V, line 2*	**35**	Yes	
36	501(c)(3) organizations Did the organization make any transfers to an exempt non-charitable related organization? *If "Yes," complete Schedule R, Part V, line 2*	**36**		No
37	Did the organization conduct more than 5 percent of its activities through an entity that is not a related organization and that is treated as a partnership for federal income tax purposes? *If "Yes," complete Schedule R, Part VI*	**37**		No

Part V Statements Regarding Other IRS Filings and Tax Compliance

					Yes	No
1a	Enter the number reported in Box 3 of Form 1096, *Annual Summary and Transmittal of U.S. Information Returns. Enter -0-* if not applicable	1a	48			
b	Enter the number of Forms W-2G included in line 1a *Enter -0-* if not applicable	1b	0			
c	Did the organization comply with backup withholding rules for reportable payments to vendors and reportable gaming (gambling) winnings to prize winners?			1c	Yes	
2a	Enter the number of employees reported on Form W-3, *Transmittal of Wage and Tax Statements* filed for the calendar year ending with or within the year covered by this return	2a	405			
b	If at least one is reported in 2a, did the organization file all required federal employment tax returns? **Note:** *If the sum of lines 1a and 2a is greater than 250, you may be required to e-file this return.*			2b	Yes	
3a	Did the organization have unrelated business gross income of $1,000 or more during the year covered by this return?			3a	Yes	
b	If "Yes," has it filed a Form 990-T for this year? *If "No," provide an explanation in Schedule O*			3b	Yes	
4a	At any time during the calendar year, did the organization have an interest in, or a signature or other authority over, a financial account in a foreign country (such as a bank account, securities account, or other financial account)?			4a		No
b	If "Yes," enter the name of the foreign country ______ See the instructions for exceptions and filing requirements for **Form TD F 90-22.1,** *Report of Foreign Bank and Financial Accounts.*					
5a	Was the organization a party to a prohibited tax shelter transaction at any time during the tax year?			5a		No
b	Did any taxable party notify the organization that it was or is a party to a prohibited tax shelter transaction?			5b		No
c	If "Yes," to 5a or 5b, did the organization file Form 8886-T, *Disclosure by Tax-Exempt Entity Regarding Prohibited Tax Shelter Transaction?*			5c		
6a	Did the organization solicit any contributions that were not tax deductible?			6a		No
b	If "Yes," did the organization include with every solicitation an express statement that such contributions or gifts were not tax deductible?			6b		
7	*Organizations that may receive deductible contributions under section 170(c).*					
a	Did the organization provide goods or services in exchange for any quid pro quo contribution of $75 or more?			7a		No
b	If "Yes," did the organization notify the donor of the value of the goods or services provided?			7b		
c	Did the organization sell, exchange, or otherwise dispose of tangible personal property for which it was required to file Form 8282?			7c		No
d	If "Yes," indicate the number of Forms 8282 filed during the year	7d				
e	Did the organization, during the year, receive any funds, directly or indirectly, to pay premiums on a personal benefit contract?			7e		No
f	Did the organization, during the year, pay premiums, directly or indirectly, on a personal benefit contract?			7f		No
g	For all contributions of qualified intellectual property, did the organization file Form 8899 as required?			7g		
h	For contributions of cars, boats, airplanes, and other vehicles, did the organization file a Form 1098-C as required?			7h		
8	*Section 501(c)(3) and other sponsoring organizations maintaining donor advised funds and section 509(a)(3) supporting organizations.* Did the supporting organization, or a fund maintained by a sponsoring organization, have excess business holdings at any time during the year?			8		
9	*Section 501(c)(3) and other sponsoring organizations maintaining donor advised funds.*					
a	Did the organization make any taxable distributions under section 4966?			9a		
b	Did the organization make a distribution to a donor, donor advisor, or related person?			9b		
10	*Section 501(c)(7) organizations.* Enter					
a	Initiation fees and capital contributions included on Part VIII, line 12	10a				
b	Gross receipts, included on Form 990, Part VIII, line 12, for public use of club facilities	10b				
11	Section 501(c)(12) organizations Enter					
a	Gross income from members or shareholders	11a				
b	Gross income from other sources (Do not net amounts due or paid to other sources against amounts due or received from them)	11b				
12a	*Section 4947(a)(1) non-exempt charitable trusts.* Is the organization filing Form 990 in lieu of Form 1041?			12a		
b	If "Yes," enter the amount of tax-exempt interest received or accrued during the year	12b				

Part VI **Governance, Management, and Disclosure** *(Sections A, B, and C request information about policies not required by the Internal Revenue Code.)*

Section A. Governing Body and Management

			Yes	No
	For each "Yes" response to lines 2-7 below, and for a "No" response to lines 8 or 9b below, describe the circumstances, processes, or changes in Schedule O. See instructions.			
1a	Enter the number of voting members of the governing body . . — 1a: 24			
b	Enter the number of voting members that are independent . . — 1b: 22			
2	Did any officer, director, trustee, or key employee have a family relationship or a business relationship with any other officer, director, trustee, or key employee?	2	Yes	
3	Did the organization delegate control over management duties customarily performed by or under the direct supervision of officers, directors or trustees, or key employees to a management company or other person?	3		No
4	Did the organization make any significant changes to its organizational documents since the prior Form 990 was filed?	4		No
5	Did the organization become aware during the year of a material diversion of the organization's assets?	5		No
6	Does the organization have members or stockholders?	6		No
7a	Does the organization have members, stockholders, or other persons who may elect one or more members of the governing body?	7a		No
b	Are any decisions of the governing body subject to approval by members, stockholders, or other persons?	7b		No
8	Did the organization contemporaneously document the meetings held or written actions undertaken during the year by the following			
a	the governing body?	8a	Yes	
b	each committee with authority to act on behalf of the governing body?	8b	Yes	
9a	Does the organization have local chapters, branches, or affiliates?	9a		No
b	If "Yes," does the organization have written policies and procedures governing the activities of such chapters, affiliates, and branches to ensure their operations are consistent with those of the organization?	9b		
10	Was a copy of the Form 990 provided to the organization's governing body before it was filed? All organizations must describe in Schedule O the process, if any, the organization uses to review the Form 990	10	Yes	
11	Is there any officer, director or trustee, or key employee listed in Part VII, Section A, who cannot be reached at the organization's mailing address? If "Yes," provide the names and addresses in Schedule O	11		No

Section B. Policies

			Yes	No
12a	Does the organization have a written conflict of interest policy? *If "No", go to line 13*	12a	Yes	
b	Are officers, directors or trustees, and key employees required to disclose annually interests that could give rise to conflicts?	12b	Yes	
c	Does the organization regularly and consistently monitor and enforce compliance with the policy? If "Yes," describe in Schedule O how this is done	12c	Yes	
13	Does the organization have a written whistleblower policy?	13	Yes	
14	Does the organization have a written document retention and destruction policy?	14	Yes	
15	Did the process for determining compensation of the following persons include a review and approval by independent persons, comparability data, and contemporaneous substantiation of the deliberation and decision			
a	The organization's CEO, Executive Director, or top management official?	15a	Yes	
b	Other officers or key employees of the organization?	15b	Yes	
	Describe the process in Schedule O			
16a	Did the organization invest in, contribute assets to, or participate in a joint venture or similar arrangement with a taxable entity during the year?	16a		No
b	If "Yes," has the organization adopted a written policy or procedure requiring the organization to evaluate its participation in joint venture arrangements under applicable Federal tax law, and taken steps to safeguard the organization's exempt status with respect to such arrangements?	16b		

Section C. Disclosure

17 List the States with which a copy of this Form 990 is required to be filed AZ

18 Section 6104 requires an organization to make its Form 1023 (or 1024 if applicable), 990, and 990-T (501(c)(3)s only) available for public inspection Indicate how you make these available Check all that apply

☐ own website ☐ another's website ☑ upon request

19 Describe in Schedule O whether (and if so, how), the organization makes its governing documents, conflict of interest policy, and financial statements available to the public See Additional Data Table

20 State the name, physical address, and telephone number of the person who possesses the books and records of the organization

ELIZABETH MONTEMAYOR
445 N 5TH ST
PHOENIX,AZ 85004
(602) 343-8508

Part VII **Compensation of Officers, Directors,Trustees, Key Employees, Highest Compensated Employees, and Independent Contractors**

Section A Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees

1a Complete this table for all persons required to be listed Use Schedule J-2 if additional space is needed

* List all of the organization's **current** officers, directors, trustees (whether individuals or organizations) and key employees regardless of amount of compensation, and current key employees Enter -0- in columns (D), (E), and (F) if no compensation was paid

* List the organization's five **current** highest compensated employees (other than an officer, director, trustee or key employee) who received reportable compensation (Box 5 of Form W-2 and/or Box 7 of Form 1099-MISC) of more than $100,000 from the organization and any related organizations

* List all of the organization's **former** officers, key employees, or highest compensated employees who received more than $100,000 of reportable compensation from the organization and any related organizations

* List all of the organization's **former directors or trustees** that received, in the capacity as a former director or trustee of the organization, more than $10,000 of reportable compensation from the organization and any related organizations

List persons in the following order individual trustees or directors, institutional trustees, officers, key employees, highest compensated employees, and former such persons

☐ Check this box if the organization did not compensate any officer, director, trustee or key employee

(A) Name and Title	(B) Average hours per week	(C) Position (check all that apply)						(D) Reportable compensation from the organization (W-2/1099MISC)	(E) Reportable compensation from related organizations (W- 2/1099-MISC)	(F) Estimated amount of other compensation from the organization and related organizations
		Individual Trustee or Director	Institutional Trustee	Officer	Key employee	Highest compensated employee	Former			

Part VII Continued

(A) Name and Title	(B) Average hours per week	(C) Position (check all that apply): Individual Trustee or Director	Institutional Trustee	Officer	Key employee	Highest compensated employee	Former	(D) Reportable compensation from the organization (W-2/1099MISC)	(E) Reportable compensation from related organizations (W-2/1099-MISC)	(F) Estimated amount of other compensation from the organization and related organizations
1b Total							▶	3,553,293	0	387,216

2 Total number of individuals (including those in 1a) who received more than $100,000 in reportable compensation from the organization ▶52

			Yes	No
3	Did the organization list any **former** officer, director or trustee, key employee, or highest compensated employee on line 1a? *If "Yes," complete Schedule J for such individual*	3		No
4	For any individual listed online 1a, is the sum of reportable compensation and other compensation from the organization and related organizations greater than $150,000? *If "Yes," complete Schedule J for such individual*	4	Yes	
5	Did any person listed on line 1a receive or accrue compensation from any unrelated organization for services rendered to the organization? *If "Yes," complete Schedule J for such person*	5		No

Section B. Independent Contractors

1 Complete this table for your five highest compensated independent contractors that received more than $100,000 of compensation from the organization

(A) Name and business address	(B) Description of services	(C) Compensation
UNIVERSITY OF TEXAS PO BOX 4390 HOUSTON, TX 772104390	RESEARCH SERVICES	333,769
UNIVERSITY OF ALABAMA AT BIRMINGHAM 1530 3RD AVENUE SOUTH BIRMINGHAM, AL 352940109	RESEARCH SERVICES	1,207,035
NORTHERN ARIZONA UNIVERSITY PO BOX 4070 FLAGSTAFF, AZ 860114070	RESEARCH SERVICES	575,534
FRED HUTCHINSON CANCER CENTER PO BOX 19024 SEATTLE, WA 981091024	RESEARCH SERVICES	562,771
ARIZONA STATE UNIVERSITY PO BOX 3602 TEMPE, AZ 852873602	RESEARCH SERVICES	487,414

2 Total number of independent contractors (including those in 1) who received more than $100,000 in compensation from the organization ▶ 12

Part VIII **Statement of Revenue**

				(A) Total Revenue	(B) Related or Exempt Function Revenue	(C) Unrelated Business Revenue	(D) Revenue Excluded from Tax under IRC 512, 513, or 514
Contributions, gifts, grants and other similar amounts	1a	Federated campaigns . . 1a					
	b	Membership dues 1b					
	c	Fundraising events 1c					
	d	Related organizations . . . 1d	4,545,907				
	e	Government grants (contributions) 1e	21,033,938				
	f	All other contributions, gifts, grants, and similar amounts not included above 1f	14,687,205				
	g	Noncash contributions included in lines 1a-1f $					
	h	**Total (Add lines 1a-1f)** . . . . ▶		40,267,050			
Program Service Revenue			Business Code				
	2a	RESEARCH CONTRACTS	900,099	17,577,572	17,577,572		
	b	CASEWORKS ADMINISTRATIVE SERVICES	561,000	500,000		500,000	
	c						
	d						
	e						
	f	All other program service revenue					
	g	**Total. Add lines 2a-2f** . . . . ▶ $ 18,077,572					
Other Revenue	3	Investment income (including dividends, interest other similar amounts) . . . . ▶		492,533			492,533
	4	Income from investment of tax-exempt bond proceeds . . ▶		0			
	5	Royalties		0			
			(i) Real / (ii) Personal				
	6a	Gross Rents					
	b	Less rental expenses					
	c	Rental income or (loss)					
	d	Net rental income or (loss) . . . . ▶					
			(i) Securities / (ii) Other				
	7a	Gross amount from sales of assets other than inventory	(i) 1,013				
	b	Less cost or other basis and sales expenses					
	c	Gain or (loss)	(i) 1,013				
	d	Net gain or (loss) . . . . ▶		1,013			1,013
	8a	Gross income from fundraising events (not including $ of contributions reported on line 1c) See Part IV, line 18 *Attach Schedule G if total exceeds $15,000* . . . . a					
	b	Less direct expenses . . . b					
	c	Net income or (loss) from fundraising events . . ▶		0			
	9a	Gross income from gaming activities See part IV, line 19 *Complete Schedule G if total exceeds $15,000* a					
	b	Less direct expenses . . . b					
	c	Net income or (loss) from gaming activities . . . ▶		0			
	10a	Gross sales of inventory, less returns and allowances . a					
	b	Less cost of goods sold . . b					
	c	Net income or (loss) from sales of inventory . . ▶		0			
		Miscellaneous Revenue	Business Code				
	11a	MANAGEMENT/SUPPORT SERVICES TO MPI	561,000	112,002		112,002	
	b	EURO CONVERSION	900,099	91,212			91,212
	c	AMNESTIX LICENSE AGREEMENT	900,099	54,167			54,167
	d	All other revenue		14,426			14,426
	e	**Total. Add lines 11a-11d** . . . . $ 271,807					
	12	**Total Revenue.** Add lines 1h, 2g, 3, 4, 5, 6d, 7d, 8c, 9c, 10c, and 11e . . . . . . ▶		59,109,975	17,577,572	612,002	653,351

Part IX **Statement of Functional Expenses**

Section 501(c)(3) and 501(c)(4) organizations must complete all columns.
All other organizations must complete column (A) but are not required to complete columns (B), (C), and (D).

	Do not include amounts reported on lines 6b, 7b, 8b, 9b, and 10b of Part VIII.	(A) Total expenses	(B) Program service expenses	(C) Management and general expenses	(D) Fundraising expenses
1	Grants and other assistance to governments and organizations in the U S See Part IV, line 21	0			
2	Grants and other assistance to individuals in the U S See Part IV, line 22	0			
3	Grants and other assistance to governments, organizations and individuals outside the U S See Part IV, lines 15 and 16	0			
4	Benefits paid to or for members	0			
5	Compensation of current officers, directors, trustees, and key employees	3,553,293	0	3,553,293	0
6	Compensation not included above, to disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B)	0			
7	Other salaries and wages	18,465,799	12,431,372		0
8	Pension plan contributions (include section 401(k) and section 403(b) employer contributions)	1,616,876	905,451	711,425	0
9	Other employee benefits	432,637	253,538	179,099	0
10	Payroll taxes	1,562,149	874,803	687,346	0
11	Fees for services (non-employees)				
a	Management	0			
b	Legal	614,558	27,897	586,661	0
c	Accounting	263,337	0	263,337	0
d	Lobbying	0			
e	Professional fundraising *See Part IV, line 17* . .	0			
f	Investment management fees	0			
g	Other	8,107,837	6,712,838	1,394,999	0
12	Advertising and promotion	198,525	27,256	171,269	0
13	Office expenses	10,457,823	8,424,088	2,033,735	0
14	Information technology	0			
15	Royalties . .	0			
16	Occupancy	4,309,253	238,717	4,070,536	0
17	Travel	1,207,192	399,488	807,704	0
18	Payments of travel or entertainment expenses for any Federal, state or local public officials	0			
19	Conferences, conventions and meetings	269,091	125,306	143,785	0
20	Interest	217,374	0	217,374	0
21	Payments to affiliates	0			
22	Depreciation, depletion, and amortization	4,473,042	2,898,635	1,574,407	0
23	Insurance	286,273	13,555	272,718	0
24	Other expenses—Itemize expenses not covered above (Expenses grouped together and labeled miscellaneous may not exceed 5% of total expenses shown on line 25 below)				
a	DUES AND SUBSCRIPTIONS	295,997	147,237	148,760	0
b	SEMINARS AND EDUCATION	245,870	12,675	233,195	0
c	RECRUITMENT	119,768	41,291	78,477	0
d	RELOCATION	113,566	31,498	82,068	0
f	All other expenses				
25	**Total functional expenses.** Add lines 1 through 24f	56,810,260	33,565,645	23,244,615	0
26	**Joint Costs.** Check ☐ if following SOP 98-2 Complete this line only if the organization reported in column (B) joint costs from a combined educational campaign and fundraising solicitation				

Part X Balance Sheet

			(A) Beginning of year		(B) End of year
Assets	1	Cash—non-interest-bearing	11,947,926	1	5,824,453
	2	Savings and temporary cash investments	6,322,927	2	12,031,549
	3	Pledges and grants receivable, net	5,659,534	3	6,241,624
	4	Accounts receivable, net	2,730,548	4	1,351,557
	5	Receivables from current and former officers, directors, trustees, key employees or other related parties *Complete Part II of Schedule L*		5	
	6	Receivables from other disqualified persons (as defined under section 4958(f)(1)) and persons described in section 4958(c)(3)(B) *Complete Part II of Schedule L*		6	
	7	Notes and loans receivable, net		7	
	8	Inventories for sale or use	0	8	90,985
	9	Prepaid expenses and deferred charges	554,111	9	944,371
	10a	Land, buildings, and equipment cost basis — 10a: 31,088,606			
	b	Less accumulated depreciation *Complete Part VI of Schedule D* — 10b: 15,371,362	9,067,723	10c	15,717,244
	11	Investments—publicly traded securities		11	
	12	Investments—other securities See Part IV, line 11 *Complete Part VII of Schedule D*		12	
	13	Investments—program-related See Part IV, line 11 *Complete Part VIII of Schedule D*		13	
	14	Intangible assets		14	
	15	Other assets See Part IV, line 11 *Complete Part IX of Schedule D*	897,708	15	515,048
	16	**Total assets.** *Add lines 1 through 15 (must equal line 34)*	37,180,477	16	42,716,831
Liabilities	17	Accounts payable and accrued expenses	5,804,781	17	5,723,876
	18	Grants payable		18	
	19	Deferred revenue	2,999,325	19	3,596,375
	20	Tax-exempt bond liabilities		20	
	21	Escrow account liability *Complete Part IV of Schedule D*		21	
	22	Payable to current and former officers, directors, trustees, key employees, highest compensated employees, and disqualified persons *Complete Part II of Schedule L*		22	
	23	Secured mortgages and notes payable to unrelated third parties	6,776,907	23	9,434,141
	24	Unsecured notes and loans payable		24	
	25	Other liabilities *Complete Part X of Schedule D*	2,504,066	25	197,085
	26	**Total liabilities.** *Add lines 17 through 25*	18,085,079	26	18,951,477
Net Assets or Fund Balances		**Organizations that follow SFAS 117, check here ▶ ☑ and complete lines 27 through 29, and lines 33 and 34.**			
	27	Unrestricted net assets	5,668,286	27	8,403,359
	28	Temporarily restricted net assets	13,427,112	28	15,361,995
	29	Permanently restricted net assets		29	
		Organizations that do not follow SFAS 117, check here ▶ ☐ and complete lines 30 through 34.			
	30	Capital stock or trust principal, or current funds		30	
	31	Paid-in or capital surplus, or land, building or equipment fund		31	
	32	Retained earnings, endowment, accumulated income, or other funds		32	
	33	Total net assets or fund balances	19,095,398	33	23,765,354
	34	Total liabilities and net assets/fund balances	37,180,477	34	42,716,831

Part XI Financial Statements and Reporting

			Yes	No
1	Accounting method used to prepare the Form 990 ☐ cash ☑ accrual ☐ other			
2a	Were the organization's financial statements compiled or reviewed by an independent accountant?	2a		No
b	Were the organization's financial statements audited by an independent accountant?	2b		No
c	If "Yes" to lines 2a or 2b, does the organization have a committee that assumes responsibility for oversight of the audit, review, or compilation of its financial statements and selection of an independent accountant?	2c		
3a	As a result of a federal award, was the organization required to undergo an audit or audits as set forth in the Single Audit Act and OMB Circular A-133?	3a	Yes	
b	If "Yes," did the organization undergo the required audit or audits?	3b	Yes	

efile GRAPHIC print - DO NOT PROCESS | As Filed Data - | DLN: 93493137026420

SCHEDULE A
(Form 990 or 990EZ)

Department of the Treasury
Internal Revenue Service

Public Charity Status and Public Support

To be completed by all section 501(c)(3) organizations and section 4947(a)(1) nonexempt charitable trusts.
Attach to Form 990 or Form 990-EZ. See separate instructions.

OMB No 1545-0047

2008

Open to Public Inspection

Name of the organization
THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE

Employer identification number
75-3065445

Part I Reason for Public Charity Status (to be completed by all organizations) (See Instructions)

The organization is not a private foundation because it is (Please check only **one** organization)

1 ☐ A church, convention of churches, or association of churches described in **Section 170(b)(1)(A)(i).**

2 ☐ A school described in **Section 170(b)(1)(A)(ii).** (Attach Schedule E)

3 ☐ A hospital or a cooperative hospital service organization described in **Section 170(b)(1)(A)(iii).** (Attach Schedule H)

4 ☐ A medical research organization operated in conjunction with a hospital described in **Section 170(b)(1)(A)(iii).** Enter the hospital's name, city, and state

5 ☐ An organization operated for the benefit of a college or university owned or operated by a governmental unit described in **Section 170(b)(1)(A)(iv).** (Complete Part II)

6 ☐ A federal, state, or local government or governmental unit described in **Section 170(b)(1)(A)(v).**

7 ☑ An organization that normally receives a substantial part of its support from a governmental unit or from the general public described in **Section 170(b)(1)(A)(vi)** (Complete Part II)

8 ☐ A community trust described in **Section 170(b)(1)(A)(vi)** (Complete Part II)

9 ☐ An organization that normally receives (1) more than 331/3% of its support from contributions, membership fees, and gross receipts from activities related to its exempt functions—subject to certain exceptions, and (2) no more than 331/3% of its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses acquired by the organization after June 30, 1975 See **Section 509(a)(2).** (Complete Part III)

10 ☐ An organization organized and operated exclusively to test for public safety See **Section 509(a)(4).** (See instructions)

11 ☐ An organization organized and operated exclusively for the benefit of, to perform the functions of, or to carry out the purposes of one or more publicly supported organizations described in section 509(a)(1) or section 509(a)(2) See **Section 509(a)(3).** Check the box that describes the type of supporting organization and complete lines 11e through 11h

a ☐ Type I **b** ☐ Type II **c** ☐ Type III - Functionally Integrated **d** ☐ Type III - Other

e ☐ By checking this box, I certify that the organization is not controlled directly or indirectly by one or more disqualified persons other than foundation managers and other than one or more publicly supported organizations described in section 509(a)(1) or section 509(a)(2)

f If the organization received a written determination from the IRS that it is a Type I, Type II or Type III supporting organization, check this box ☐

g Since August 17, 2006, has the organization accepted any gift or contribution from any of the following persons?

		Yes	No
(i) a person who directly or indirectly controls, either alone or together with persons described in (ii) and (iii) below, the governing body of the the supported organization?	11g(i)		
(ii) a family member of a person described in (i) above?	11g(ii)		
(iii) a 35% controlled entity of a person described in (i) or (ii) above?	11g(iii)		

h Provide the following information about the organizations the organization supports

(i) Name of Supported Organization	(ii) EIN	(iii) Type of organization (described on lines 1- 9 above or IRC section (See Instructions))	(iv) Is the organization in col (i) listed in your governing document?		(v) Did you notify the organization in col (i) of your support?		(vi) Is the organization in col (i) organized in the U S ?		(vii) Amount of support?
			Yes	No	Yes	No	Yes	No	
Total									

Part II **Support Schedule for Organizations Described in IRC 170(b)(1)(A)(iv) and 170(b)(1)(A)(vi)**
(Complete only if you checked the box on line 5, 7, or 8 of Part I.)

Public Support

Calendar year (or fiscal year beginning in)	(a) 2004	(b) 2005	(c) 2006	(d) 2007	(e) 2008	(f) Total
1 Gifts, grants, contributions, and membership fees received (Do not include any "unusual grants ")	16,052,958	29,992,149	30,038,918	48,715,607	40,267,050	165,066,682
2 Tax revenues levied for the organization's benefit and either paid to or expended on its behalf						
3 The value of services or facilities furnished by a governmental unit to the organization without charge						
4 **Total.** Add line 1-3	16,052,958	29,992,149	30,038,918	48,715,607	40,267,050	165,066,682
5 The portion of total contribution by each person (other than a government unit or publicly supported organization) included on line 1 that exceed 2% of the amount shown on line 11, column (f)						26,764,822
6 **Public Support** subtract line 5 from line 4						138,301,860

Total Support

Calendar year (or fiscal year beginning in)	(a) 2004	(b) 2005	(c) 2006	(d) 2007	(e) 2008	(f) Total
7 Amounts from line 4	16,052,958	36,506	30,038,918	48,715,607	40,267,050	165,066,682
8 Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources	10,586	36,506	83,242	230,227	492,533	853,094
9 Net income from unrelated business activities, whether or not the business is regularly carried on				65,317		65,317
10 Other income Do not include gain or loss from the sale of capital assets (Explain in Part IV)	2,118,803	761,982	874,059	204,892	271,807	4,231,543
11 **Total Support** (Add lines 7 through 10)						170,216,636

12 Gross receipts from related activities, etc (See instructions) | 12 | 75,462,393

13 **First Five Years.** If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a 501(c)(3) organization, check this box and **stop here** ☐

Computation of Public Support Percentage

14 Public Support Percentage for 2008 (line 6 column (f) divided by line 11 column (f)) | 14 | **81.251 %**

15 Public Support Percentage for 2007 Schedule A, Part IV-A, line 26f | 15 | **74.892 %**

16a **33 1/3% Test - 2008.** If the organization did not check the box on line 13, and line 14 is 33 1/3% or more, check this box and **stop here.** The organization qualifies as a publicly supported organization ☑

b **33 1/3% Test - 2007.** If the organization did not check the box on line 13 or 16a, and line 15 is 33 1/3% or more, check this box and **stop here.** The organization qualifies as a publicly supported organization ☐

17a **10% Facts and Circumstances Test - 2008.** If the organization did not check a box on line 13, 16a, or 16b and line 14 is 10% or more, and if the organization meets the "facts and circumstances" test, check this box and **stop here.** Explain in Part IV how the organization meets the "facts and circumstances" test The organization qualifies as a publicly supported organization ☐

b **10% Facts and Circumstances Test - 2007.** If the organization did not check a box on line 13, 16a, 16b, or 17a and line 15 is 10% or more, and if the organization meets the "facts and circumstances" test, check this box and **stop here.** Explain in Part IV how the organization meets the "facts and circumstances" test The organization qualifies as a publicly supported organization ☐

18 **Private Foundation.** If the organization did not check the box on line 13, 16a, 16b, 17a or 17b, check this box and see instructions ☐

Part III **Support Schedule for Organizations Described in IRC 509(a)(2)**
(Complete only if you checked the box on line 9 of Part I.)

Section A. Public Support

Calendar year (or fiscal year beginning in)	**(a)** 2004	**(b)** 2005	**(c)** 2006	**(d)** 2007	**(e)** 2008	**(f)** Total
1 Gifts, grants, contributions, and membership fees received (Do not include any "unusual grants ")						
2 Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose						
3 Gross receipts from activities that are not an unrelated trade or business under section 513						
4 Tax revenues levied for the organization's benefit and either paid to or expended on its behalf						
5 The value of services or facilities furnished by a governmental unit to the organization without charge						
6 **Total** Add lines 1-5						
7a Amounts included on lines 1, 2, and 3 received from disqualified persons						
b Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of 1% of the total of lines 9, 10c, 11, and 12 for the year or $5,000						
c Total of lines 7a and 7b						
8 **Public Support** (Substract line 7c from line 6)						

Total Support

Calendar year (or fiscal year beginning in)	**(a)** 2004	**(b)** 2005	**(c)** 2006	**(d)** 2007	**(e)** 2008	**(f)** Total
9 Amounts from line 6						
10a Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources						
b Unrelated business taxable income (less section 511 taxes) from businesses acquired after 30 June, 1975						
c Add lines 10a and 10b						
11 Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on						
12 Other income Do not include gain or loss from the sale of capital assets (Explain in Part IV)						
13 **Total Support** (Add lines 9, 10c, 11 and 12)						

14 **First Five Years** If the Form 990 is for the organization's first, second, third, fourth, or fifth tax year as a 501(c)(3) organization, check this box and **stop here** ▶☐

Computation of Public Support Percentage

15 Public Support Percentage for 2008 (line 8 column (f) divided by line 13 column (f))	**15**	
16 Public Support Percentage for 2007 Schedule A, Part IV-A, line 27g	**16**	

Computation of Investment Income Percentage

17 Investment Income Percentage for **2008** (line 10c column (f) divided by line 13 column (f))	**17**	
18 Investment Income Percentage from **2007** Schedule A, Part IV-A, line 27h	**18**	

19a **33 1/3% Tests - 2008.** If the organization did not check the box on line 14, and line 15 is more than 33 1/3%, and line 17 is not more than 33 1/3%, check this box and **stop here.** The organization qualifies as a publicly supported organization ▶☐

b **33 1/3% Tests - 2007.** If the organization did not check a box on line 14 or line 19a, and line 16 is more than 33 1/3% and line 18 is not more than 33 1/3%, check this box and **stop here.** The organization qualifies as a publicly supported organization ▶☐

20 **Private Foundation** If the organization did not check a box on line 14, 19a or 19b, check this box and see instructions ▶☐

Part IV **Supplemental Information.** Complete this part to provide the information required by Part II, line 10; Part II, line 17a or 17b, or Part III, line 12. Provide and any other additional information. (see instructions)

Facts and Circumstances Test

Name of organization
THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE

Employer identification number
75-3065445

Part III ***Exclusively*** **religious, charitable, etc., individual contributions to section 501(c)(7), (8), or (10) organizations aggregating more than $1,000 for the year.** (Complete columns **(a)** through **(e) and** the following line entry)
For organizations completing Part III, enter the total of *exclusively* religious, charitable, etc , contributions of **$1,000 or less** for the year (Enter this information once See instructions) ▶ $ 0

(a) No. from Part I	(b) Purpose of gift	(c) Use of gift	(d) Description of how gift is held

(e) Transfer of gift

Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a) No. from Part I	(b) Purpose of gift	(c) Use of gift	(d) Description of how gift is held

(e) Transfer of gift

Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a) No. from Part I	(b) Purpose of gift	(c) Use of gift	(d) Description of how gift is held

(e) Transfer of gift

Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

(a) No. from Part I	(b) Purpose of gift	(c) Use of gift	(d) Description of how gift is held

(e) Transfer of gift

Transferee's name, address, and ZIP 4	Relationship of transferor to transferee

Additional Data

Software ID:
Software Version:
EIN: 75-3065445
Name: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE

Form 990, Part VII - Section Aaa

(A) Name and Title	(B) Average hours per week	(C) Position (check all that apply)						(D) Reportable compensation from the organization (W-2/1099MISC)	(E) Reportable compensation from related organizations (W- 2/1099-MISC)	(F) Estimated amount of other compensation from the organization and related organizations
		Individual Trustee or Director	Institutional Trustee	Officer	Key employee	Highest compensated employee	Former			
JEFFREY M TRENT PHD , PRESIDENT AND SCIENTIFIC DIR	40 0	X		X				797,020	0	196,331
BETSEY BAYLESS , DIRECTOR	1 0	X						0	0	0
RICHARD L BOALS , DIRECTOR	1 0	X						0	0	0
GOVERNOR JAN BREWER , DIRECTOR	1 0	X						0	0	0
JOSE CARDENAS , DIRECTOR/CHAIRMAN	1 0	X		X				0	0	0
SUSAN CLARK-JOHNSON , DIRECTOR	1 0	X						0	0	0
MICHAEL CROW PHD , DIRECTOR	1 0	X						0	0	0
BENNETT DORRANCE , DIRECTOR/SECRETARY	1 0	X		X				0	0	0
ROBERT BULLA , DIRECTOR	1 0	X						0	0	0
HONORABLE DIANE ENOS , DIRECTOR	1 0	X						0	0	0
PETER S FINE , DIRECTOR	1 0	X						0	0	0
BERT A GETZ , DIRECTOR	1 0	X						0	0	0
JOHN MURPHY , DIRECTOR/TREASURER	1 0	X		X				0	0	0
JEFFREY MOORAD , DIRECTOR	1 0	X						0	0	0
JOHN D HAEGER PHD , DIRECTOR	1 0	X						0	0	0
KEITH R MCKENNON , DIRECTOR	1 0	X						0	0	0
HONORABLE PHIL GORDON , DIRECTOR	1 0	X						0	0	0
T LON OWEN PHD , DIRECTOR	1 0	X						0		0
CINDY PARSEGHIAN , DIRECTOR	1 0	X						0	0	0
WILLIAM J POST , DIRECTOR	1 0	X						0	0	0
FRANKLYN G PRENDERGAST MD PHD , DIRECTOR	1 0	X						0	0	0
HONORABLE JIM SLATTERY , DIRECTOR	1 0	X						0	0	0
ROBERT N SHELTON PHD , DIRECTOR	1 0	X						0	0	0
RICHARD SILVERMAN , DIRECTOR	1 0	X						0	0	0
GOVERNOR JANET NAPOLITANO , DIRECTOR (THROUGH 1/2009)	1 0	X						0	0	0
TERESA BURLESON , CHIEF OPERATING OFFICER	40 0			X				362,159	0	13,736
ELIZABETH MONTEMAYOR , CHIEF FINANCIAL OFFICER	40 0			X				236,144	0	19,287
DANIEL VON HOFF , EXECUTIVE VICE PRESIDENT	40 0				X			499,026	0	77,530
MARY ANNE GUERRA , PRESIDENT, TGEN ACCELERATORS	40 0				X			405,349	0	15,865
EDWARD SUH , CHIEF INFORMATION OFFICER	40 0					X		292,849	0	14,175

Form 990, Part VII - Section Aaa

(A) Name and Title	(B) Average hours per week	(C) Position (check all that apply) Individual Trustee or Director	Institutional Trustee	Officer	Key employee	Highest compensated employee	Former	(D) Reportable compensation from the organization (W-2/1099MISC)	(E) Reportable compensation from related organizations (W- 2/1099-MISC)	(F) Estimated amount of other compensation from the organization and related organizations
SPYRO MOUSSES , SENIOR INVESTIGATOR	40 0					X		272,832	0	14,175
JOHN CARPTEN , SENIOR INVESTIGATOR	40 0					X		234,319	0	13,746
STEPHANIE MCRAE , GENERAL COUNSEL	40 0					X		234,078	0	8,807
DAVID DUGGAN , INVESTIGATOR	40 0					X		219,517	0	13,564

SCHEDULE D (Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Financial Statements

▶ Attach to Form 990. To be completed by organizations that answered "Yes," to Form 990, Part IV, line 6, 7, 8, 9, 10, 11, or 12.

OMB No 1545-0047

2008

Open to Public Inspection

Name of the organization
THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE

Employer identification number
75-3065445

Part I **Organizations Maintaining Donor Advised Funds or Other Similar Funds or Accounts.** Complete if the organization answered "Yes" to Form 990, Part IV, line 6.

		(a) Donor advised funds	(b) Funds and other accounts
1	Total number at end of year		
2	Aggregate Contributions to (during year)		
3	Aggregate Grants from (during year)		
4	Aggregate value at end of year		

5 Did the organization inform all donors and donor advisors in writing that the assets held in donor advised funds are the organization's property, subject to the organization's exclusive legal control? ☐ Yes ☐ No

6 Did the organization inform all grantees, donors, and donor advisors in writing that grant funds may be used only for charitable purposes and not for the benefit of the donor or donor advisor or other impermissible private benefit? ☐ Yes ☐ No

Part II **Conservation Easements.** Complete if the organization answered "Yes" to Form 990, Part IV, line 7.

1 Purpose(s) of conservation easements held by the organization (check all that apply)

☐ Preservation of land for public use (e g , recreation or pleasure)
☐ Preservation of an historically importantly land area
☐ Protection of natural habitat
☐ Preservation of certified historic structure
☐ Preservation of open space

2 Complete lines 2a–2d if the organization held a qualified conservation contribution in the form of a conservation easement on the last day of the tax year

			Held at the End of the Year
a	Total number of conservation easements	2a	
b	Total acreage restricted by conservation easements	2b	
c	Number of conservation easements on a certified historic structure included in (a)	2c	
d	Number of conservation easements included in (c) acquired after 8/17/06	2d	

3 Number of conservation easements modified, transferred, released, extinguished, or terminated by the organization during the taxable year ▶

4 Number of states where property subject to conservation easement is located ▶

5 Does the organization have a written policy regarding the periodic monitoring, inspection, violations, and enforcement of the conservation easements it holds? ☐ Yes ☐ No

6 Staff or volunteer hours devoted to monitoring, inspecting and enforcing easements during the year ▶

7 Amount of expenses incurred in monitoring, inspecting, and enforcing easements during the year ▶ $

8 Does each conservation easement reported on line 2(d) above satisfy the requirements of section 170(h)(4)(B)(i) and 170(h)(4)(B)(ii)? ☐ Yes ☐ No

9 In Part XIV, describe how the organization reports conservation easements in its revenue and expense statement, and balance sheet, and include, if applicable, the text of the footnote to the organization's financial statements that describes the organization's accounting for conservation easements

Part III **Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets.** Complete if the organization answered "Yes" to Form 990, Part IV, line 8.

1a If the organization elected, as permitted under SFAS 116, not to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education or research in furtherance of public service, provide, in Part XIV, the text of the footnote to its financial statements that describes these items

b If the organization elected, as permitted under SFAS 116, to report in its revenue statement and balance sheet works of art, historical treasures, or other similar assets held for public exhibition, education, or research in furtherance of public service, provide the following amounts relating to these items

(i) Revenues included in Form 990, Part VIII, line 1 ▶ $

(ii) Assets included in Form 990, Part X ▶ $

2 If the organization received or held works of art, historical treasures, or other similar assets for financial gain, provide the following amounts required to be reported under SFAS 116 relating to these items

a Revenues included in Form 990, Part VIII, line 1 ▶ $

b Assets included in Form 990, Part X ▶ $

Part III Organizations Maintaining Collections of Art, Historical Treasures, or Other Similar Assets *(continued)*

3 Using the organization's accession and other records, check any of the following that are a significant use of its collection items (check all that apply)

a ☐ Public exhibition
b ☐ Scholarly research
c ☐ Preservation for future generations
d ☐ Loan or exchange programs
e ☐ Other

4 Provide a description of the organization's collections and explain how they further the organization's exempt purpose in Part XIV

5 During the year, did the organization solicit or receive donations of art, historical treasures or other similar assets to be sold to raise funds rather than to be maintained as part of the organization's collection? ☐ Yes ☐ No

Part IV Trust, Escrow and Custodial Arrangements. Complete if the organization answered "Yes" to Form 990, Part IV, line 9, or reported an amount on Form 990, Part X, line 21.

1a Is the organization an agent, trustee, custodian or other intermediary for contributions or other assets not included on Form 990, Part X? ☐ Yes ☐ No

b If "Yes," explain why in Part XIV and complete the following table

			Amount
c	Beginning balance	1c	
d	Additions during the year	1d	
e	Distributions during the year	1e	
f	Ending balance	1f	

2a Did the organization include an amount on Form 990, Part X, line 21? ☐ Yes ☐ No

b If "Yes," explain the arrangement in Part XIV

Part V Endowment Funds. Complete if the organization answered "Yes" to Form 990, Part IV, line 10.

		(a) Current Year	(b) Prior Year	(c) Two Years Back	(d) Three Years Back	(e) Four Years Back
1a	Beginning of year balance	6,309,126				
b	Contributions	10,000				
c	Investment earnings or losses	422,245				
d	Grants or scholarships					
e	Other expenditures for facilities and programs	367,407				
f	Administrative expenses					
g	End of year balance	6,373,964				

2 Provide the estimated percentage of the year end balance held as

a Board designated or quasi-endowment ▶

b Permanent endowment ▶

c Term endowment ▶ 100 %

3a Are there endowment funds not in the possession of the organization that are held and administered for the organization by

			Yes	No
	(i) unrelated organizations	3a(i)		No
	(ii) related organizations	3a(ii)		No
b	If "Yes" to 3a(ii), are the related organizations listed as required on Schedule R?	3b	Yes	

4 Describe in Part XIV the intended uses of the organization's endowment funds

Part VI Investments—Land, Buildings, and Equipment. See Form 990, Part X, line 10.

Description of investment	(a) Cost or other basis (investment)	(b) Cost or other basis (other)	(c) Depreciation	(d) Book value
1a Land				
b Buildings				
c Leasehold improvements		4,610,142	824,407	3,785,735
d Equipment		23,090,302	12,129,670	10,960,632
e Other		3,388,162	2,417,285	970,877
Total. Add lines 1a-1e *(Column (d) should equal Form 990, Part X, column (B), line 10(c).)* ▶				15,717,244

Part VII Investments—Other Securities. See Form 990, Part X, line 12.

(a) Description of security or cateory (including name of security)	(b) Book value	(c) Method of valuation Cost or end-of-year market value
Financial derivatives and other financial products		
Closely-held equity interests		
Other		
Total. *(Column (b) should equal Form 990, Part X, col (B) line 12)* ▶		

Part VIII Investments—Program Related. See Form 990, Part X, line 13.

(a) Description of investment type	(b) Book value	(c) Method of valuation Cost or end-of-year market value
Total. *(Column (b) should equal Form 990, Part X, col (B) line 13)* ▶		

Part IX Other Assets. See Form 990, Part X, line 15.

(a) Description	(b) Book value
ALL OTHER ASSETS	211,678
DUE FROM FOUNDATION	303,370
Total. *(Column (b) should equal Form 990, Part X, col.(B) line 15.)* . . . . ▶	

Part X Other Liabilities. See Form 990, Part X, line 25.

(a) Description of Liability	(b) Amount
Federal Income Taxes	
ALL OTHER LIABILITIES	197,085
Total. *(Column (b) should equal Form 990, Part X, col (B) line 25)* ▶	197,085

In Part XIV, provide the text of the footnote to the organization's financial statements that reports the organization's liability for uncertain tax positions under FIN 48

Part XI Reconciliation of Change in Net Assets from Form 990 to Financial Statements

1	Total revenue (Form 990, Part VIII, column (A), line 12)	1	
2	Total expenses (Form 990, Part IX, column (A), line 25)	2	
3	Excess or (deficit) for the year Subtract line 2 from line 1	3	
4	Net unrealized gains (losses) on investments	4	
5	Donated services and use of facilities	5	
6	Investment expenses	6	
7	Prior period adjustments	7	
8	Other (Describe in Part XIV)	8	
9	Total adjustments (net) Add lines 4 - 8	9	
10	Excess or (deficit) for the year per financial statements Combine lines 3 and 9	10	

Part XII Reconciliation of Revenue per Audited Financial Statements With Revenue per Return

1	Total revenue, gains, and other support per audited financial statements			1	
2	Amounts included on line 1 but not on Form 990, Part VIII, line 12				
a	Net unrealized gains on investments	2a			
b	Donated services and use of facilities	2b			
c	Recoveries of prior year grants	2c			
d	Other (Describe in Part XIV)	2d			
e	Add lines **2a** through **2d**			2e	
3	Subtract line **2e** from line **1**			3	
4	Amounts included on Form 990, Part VIII, line 12, but not on line **1**				
a	Investment expenses not included on Form 990, Part VIII, line 7b	4a			
b	Other (Describe in Part XIV)	4b			
c	Add lines **4a** and **4b**			4c	
5	Total Revenue Add lines **3** and **4c.** (This should equal Form 990, Part I, line 12)			5	

Part XIII Reconciliation of Expenses per Audited Financial Statements With Expenses per Return

1	Total expenses and losses per audited financial statements			1	
2	Amounts included on line 1 but not on Form 990, Part IX, line 25				
a	Donated services and use of facilities	2a			
b	Prior year adjustments	2b			
c	Losses reported on Form 990, Part IX, line 25	2c			
d	Other (Describe in Part XIV)	2d			
e	Add lines **2a** through **2d**			2e	
3	Subtract line **2e** from line **1**			3	
4	Amounts included on Form 990, Part IX, line 25, but not on line **1:**				
a	Investment expenses not included on Form 990, Part VIII, line 7b	4a			
b	Other (Describe in Part XIV)	4b			
c	Add lines **4a** and **4b**			4c	
5	Total expenses Add lines **3** and **4c.** (This should equal Form 990, Part I, line 18)			5	

Part XIV Supplemental Information

Complete this part to provide the descriptions required for Part II, lines 3, 5, and 9, Part III, lines 1a and 4, Part XIV, lines 1b and 2b, Part V, line 4, Part X, Part XI, line 8, Part XII, lines 2d and 4b, and Part XIII, lines 2d and 4b

Identifier	Return Reference	Explanation
SCHEDULE D, PART V - ENDOWMENTS		TGEN'S policy for appropriating the distribution of its summer internship program endowment has been designed to support a specific number of summer interns each year for the next 25 years The Institute considered the long-term expected return on its endowment

SCHEDULE F
(Form 990)

Department of the Treasury
Internal Revenue Service

Statement of Activities Outside the United States

▶ Attach to Form 990. Complete if the organization answered "Yes" to Form 990, Part IV, line 14b.

OMB No 1545-0047

2008

Open to Public Inspection

Name of the organization
THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE

Employer identification number
75-3065445

Part I General Information on Activities Outside the United States. Complete if the organization answered "Yes" to Form 990, Part IV, line 14b.

1 **For grantmakers.** Does the organization maintain records to substantiate the amount of the grants or assistance, the grantees' eligibility for the grants or assistance, and the selection criteria used to award the grants or assistance . . . . ☐ Yes ☑ No

2 **For grantmakers.** Describe in Part IV the organization's procedures for monitoring the use of grant funds outside the United States

3 Activites per Region (Use Schedule F-1 (Form 990) if additional space is needed)

(a) Region	**(b)** Number of offices in the region	**(c)** Number of employees or agents in region	**(d)** Activities conducted in region (by type) (i e , fundraising, program services, grants to recipients located in the region)	**(e)** If activity listed in (d) is a program service, describe specific type of service(s) in region	**(f)** Total expenditures in region
Europe (Including Iceland and Greenland)	0	0	Program Services	SOFTWARE DEVELOPMENT	
Totals . . . . . . ▶	0	0			

Part II **Grants and Other Assistance to Organizations or Entities Outside the United States.** Complete if the organization answered "Yes" to Form 990, Part IV, line 15, for any recipient who received more than $5,000. Check this box if no one recipient received more than $5,000 . . . . ▶ ☐
Use Schedule F-1 if additional space is needed.

1 (a) Name of organization	(b) IRS code section and EIN (if applicable)	(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement	(g) Amount of of non-cash assistance	(h) Description of non-cash assistance	(i) Method of valuation (book, FMV, appraisal, other)

2 Enter total number of organizations that are recognized as charities by the foreign country or for which the grantee or counsel has provided a section 501(c)(3) equivalency letter . . . . ▶

3 Enter total number of other organizations or entities . . . . ▶

Part III **Grants and Other Assistance to Individuals Outside the United States.** Complete if the organization answered "Yes" to Form 990, Part IV, line 16. Use Schedule F-1 (Form 990) if additional space is needed.

(a) Type of grant or assistance	**(b)** Region	**(c)** Number of recipients	**(d)** Amount of cash grant	**(e)** Manner of cash disbursement	**(f)** Amount of non-cash assistance	**(g)** Description of non-cash assistance	**(h)** Method of valuation (book, FMV, appraisal, other)

Part IV **Supplemental Information**

Complete this part to provide the information required in Part I, line 2, and any other additional information.

Identifier	ReturnReference	Explanation

Additional Data

Return to Form

Software ID:
Software Version:
EIN: 75-3065445
Name: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE

Form 990 Schedule F Part II - Grants and Other Assistance to Organizations or Entities Outside The United States

(a) Name of organization	(b) IRS code section and EIN (if applicable)	(c) Region	(d) Purpose of grant	(e) Amount of cash grant	(f) Manner of cash disbursement	(g) Amount of non-cash assistance	(h) Description of non-cash assistance	(i) Method of valuation (book, FMV, appraisal, other)

Schedule J (Form 990)

Department of the Treasury
Internal Revenue Service

Compensation Information

For certain Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees
▶ Attach to Form 990. To be completed by organizations that answered "Yes" to Form 990, Part IV, line 23.

OMB No 1545-0047

2008

Open to Public Inspection

Name of the organization
THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE

Employer identification number
75-3065445

Part I Questions Regarding Compensation

			Yes	No
1a	Check the appropiate box(es) ıf the organızatıon provided any of the following to or for a person lısted ın Form 990, Part VII, Sectıon A, lıne 1a Complete Part III to provıde any relevant ınformatıon regardıng these ıtems ☑ Fırst class or charter travel ☐ Travel for companıons ☐ Tax ıdemnıfıcatıon and gross-up payments ☐ Dıscretıonary spendıng account ☐ Housıng allowance or resıdence for personal use ☐ Payments for busıness use of personal resıdence ☑ Health or socıal club dues or ınıtıatıon fees ☐ Personal servıces (e g , maıd, chauffeur, chef)			
b	If lıne 1a ıs checked, dıd the organızatıon follow a wrıtten polıcy regardıng payment or reımbursement or provısıon of all the expenses descrıbed above? If "No," complete Part III to explaın	**1b**	Yes	
2	Dıd the organızatıon requıre substantıatıon prıor to reımbursıng or allowıng expenses ıncurred by all officers, dırectors, trustees, and the CEO/Executıve Dırector, regardıng the ıtems checked ın lıne 1a?	**2**	Yes	
3	Indıcate whıch, ıf any, of the followıng the organızatıon uses to establısh the compensatıon of the organızatıon's CEO/Executıve Dırector Check all that apply ☑ Compensatıon commıttee ☑ Independent compensatıon consultant ☐ Form 990 of other organızatıons ☐ Wrıtten employment contract ☑ Compensatıon survey or study ☑ Approval by the board or compensatıon commıttee			
4	Durıng the year, dıd any person lısted ın Form 990, Part VII, Sectıon A, lıne 1a			
a	Receıve a severance payment or change of control payment?	**4a**		No
b	Partıcıpate ın, or receıve payment from, a supplemental nonqualıfıed retırement plan?	**4b**		No
c	Partıcıpate ın, or receıve payment from, an equıty-based compensatıon arrangement?	**4c**		No
	If "Yes" to any of lınes 4a-c, lıst the persons and provıde the applıcable amounts for each ıtem ın Part III			
	501(c)(3) and 501(c)(4) organizations only must complete lines 5-8.			
5	For persons lısted ın form 990, Part VII, Sectıon A, lıne 1a, dıd the organızatıon pay or accrue any compensatıon contıngent on the revenues of			
a	The organızatıon?	**5a**		No
b	Any related organızatıon?	**5b**		No
	If "Yes," to lıne 5a or 5b, descrıbe ın Part III			
6	For persons lısted ın form 990, Part VII, Sectıon A, lıne 1a, dıd the organızatıon pay or accrue any compensatıon contıngent on the net earnıngs of			
a	The organızatıon?	**6a**		No
b	Any related organızatıon?	**6b**		No
	If "Yes," to lıne 6a or 6b, descrıbe ın Part III			
7	For persons lısted ın form 990, Part VII, Sectıon A, lıne 1a, dıd the organızatıon provıde any non-fıxed payments not descrıbed ın lınes 5 and 6? If "Yes," descrıbe ın Part III	**7**	Yes	
8	Were any amounts reported ın Form 990, Part VII, paıd or accured pursuant to a contract that was subject to the ınıtıal contract exceptıon descrıbed ın Regs sectıon 53 4958-4(a)(3)? If "Yes," descrıbe ın Part III	**8**		No

Part II Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees. Use Schedule J-1 if additional space needed.

For each individual whose compensation must be reported in Schedule J, report compensation from the organization on row (i) and from related organizations described in the instructions on row (ii) Do not list any individuals that are not listed on Form 990, Part VII

Note. The sum of columns (B)(i)-(iii) must equal the applicable column (D) or column (E) amounts on Form 990, Part VII, line 1a

(A) Name		(B) Breakdown of W-2 and/or 1099-MISC compensation			(C) Deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation reported in prior Form 990 or Form 990-EZ
		(i) Base compensation	(ii) Bonus & incentive compensation	(iii) Other compensation				
JEFFREY M TRENT PHD	(i)	707,979	51,273	37,768	189,252	7,079	993,351	357,303
	(ii)	0	0	0	0	0	0	0
TERESA BURLESON	(i)	324,659	22,000	15,500	9,200	4,536	375,895	181,138
	(ii)	0	0	0	0	0	0	0
ELIZABETH MONTEMAYOR	(i)	202,827	22,000	11,317	8,545	10,742	255,431	119,654
	(ii)	0	0	0	0	0	0	0
DANIEL VON HOFF	(i)	465,526	13,000	20,500	74,200	3,330	576,556	253,446
	(ii)	0	0	0	0	0	0	0
MARY ANNE GUERRA	(i)	328,274	55,567	21,508	9,200	6,665	421,214	175,255
	(ii)	0	0	0	0	0	0	0
EDWARD SUH	(i)	227,937	33,014	31,898	9,200	4,975	307,024	150,781
	(ii)	0	0	0	0	0	0	0
SPYRO MOUSSES	(i)	202,488	57,141	13,203	9,200	4,975	287,007	155,767
	(ii)	0	0	0	0	0	0	0
JOHN CARPTEN	(i)	211,362	9,717	13,240	8,771	4,975	248,065	112,301
	(ii)	0	0	0	0	0	0	0
STEPHANIE MCRAE	(i)	196,050	22,610	15,418	8,674	133	242,885	113,381
	(ii)	0	0	0	0	0	0	0
DAVID DUGGAN	(i)	175,365	29,869	14,283	8,161	5,403	233,081	0
	(ii)	0	0	0	0	0	0	0
	(i)							
	(ii)							
	(i)							
	(ii)							
	(i)							
	(ii)							

Part III Supplemental Information

Complete this part to provide the information, explanation, or descriptions required for Part I, lines 1a, 1b, 4c, 5a, 5b, 6a, 6b, 7, and 8 Also complete this part for any additional information

Identifier	Return Reference	Explanation
SCHEDULE J SUPPLEMENTAL INFORMATION		SCHEDULE J, PART I, LINE 1 - First Class Travel is permitted by Executive staff only and must, per TGEN policy, be pre-approved by the Chief Operating Officer TGEN does provide membership to Dr Jeffrey Trent, President of TGEN, at a Country Club This expense was pre-approved by the Chief Operating Officer These expenses were not considered as taxable compensation to the recipient SCHEDULE J, PART I, LINE 7 - Some of the persons listed in Form 990, Part VII were paid bonuses which were based on accomplishments of specific milestones and/or performance bases SCHEDULE J, PART II, COL C - Dr Trent's compensation agreement calls for a bonus payment of $500,000 plus earnings or losses payable effective June 30, 2012 Annual increments are reported as deferred Dr Von Hoff's compensation agreement calls for a bonus payment of $400,000 payable effective December 31, 2008 Annual increments are reported as deferred

Additional Data

Return to Form

Software ID:
Software Version:
EIN: 75-3065445
Name: THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE

Form 990, Schedule J, Part II - Officers, Directors, Trustees, Key Employees, and Highest Compensated Employees

(A) Name		(B) Breakdown of W-2 and/or 1099-MISC compensation			(C) Deferred compensation	(D) Nontaxable benefits	(E) Total of columns (B)(i)-(D)	(F) Compensation reported in prior Form 990 or Form 990-EZ
		(i) Base Compensation	(ii) Bonus & incentive compensation	(iii) Other compensation				
JEFFREY M TRENT PHD	(i)	707,979	51,273	37,768	189,252	7,079	993,351	357,303
	(ii)	0	0	0	0	0	0	0
TERESA BURLESON	(i)	324,659	22,000	15,500	9,200	4,536	375,895	181,138
	(ii)	0	0	0	0	0	0	0
ELIZABETH MONTEMAYOR	(i)	202,827	22,000	11,317	8,545	10,742	255,431	119,654
	(ii)	0	0	0	0	0	0	0
DANIEL VON HOFF	(i)	465,526	13,000	20,500	74,200	3,330	576,556	253,446
	(ii)	0	0	0	0	0	0	0
MARY ANNE GUERRA	(i)	328,274	55,567	21,508	9,200	6,665	421,214	175,255
	(ii)	0	0	0	0	0	0	0
EDWARD SUH	(i)	227,937	33,014	31,898	9,200	4,975	307,024	150,781
	(ii)	0	0	0	0	0	0	0
SPYRO MOUSSES	(i)	202,488	57,141	13,203	9,200	4,975	287,007	155,767
	(ii)	0	0	0	0	0	0	0
JOHN CARPTEN	(i)	211,362	9,717	13,240	8,771	4,975	248,065	112,301
	(ii)	0	0	0	0	0	0	0
STEPHANIE MCRAE	(i)	196,050	22,610	15,418	8,674	133	242,885	113,381
	(ii)	0	0	0	0	0	0	0
DAVID DUGGAN	(i)	175,365	29,869	14,283	8,161	5,403	233,081	0
	(ii)	0	0	0	0	0	0	0

efile GRAPHIC print - DO NOT PROCESS	As Filed Data -	DLN: 93493137026420

Schedule L
(Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Transactions with Interested Persons

▶ Attach to Form 990 or Form 990-EZ.
▶ To be completed by organizations that answered "Yes" on Form 990, Part IV, lines 25a, 25b, 26, 27, 28a, 28b, or 28c, or Form 990-EZ, Part V lines 38b or 40b.

OMB No 1545-0047

2008

Open to Public Inspection

Name of the organization
THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE

Employer identification number
75-3065445

Part I Excess Benefit Transactions (section 501(c)(3) and section 501 (c)(4) organizations only).

To be completed by organizations that answered "Yes" on Form 990, Part IV, line 25a or 25b, or Form 990-EZ, Part V, line 40b

1 (a) Name of disqualified person	(b) Description of transaction	(c) Corrected? Yes	No

2 Enter the amount of tax imposed on the organization managers or disqualified persons during the year under section 4958 . . . . . ▶ $

3 Enter the amount of tax, if any, on line 2, above, reimbursed by the organization . . . . . ▶ $

Part II Loans to and/or From Interested Persons

To be completed by organizations that answered "Yes" on Form 990, Part IV, line 26, or Form 990-EZ, Part V, line 38a

(a) Name of interested person and purpose	(b) Loan to or from the organization? To	From	(c) Original principal amount	(d) Balance due	(e) In default? Yes	No	(f) Approved by board or committee? Yes	No	(g) Written agreement? Yes	No
Total . . . . . ▶ $										

Part III Grants or Assistance Benefitting Interested Persons

To be completed by organizations that answered "Yes" on Form 990, Part IV, line 27.

(a) Name of interested person	(b) Relationship between interested person and the organization	(c) Amount of grant or type of assistance

Part IV Business Transactions Involving Interested Persons

To be completed by organizations that answered "Yes" on Form 990, Part IV, line 28a, 28b, or 28c.

(a) Name of interested person	(b) Relationship between interested person and the organization	(c) Amount of transaction	(d) Description of transaction	(e) Sharing of organization's revenues? Yes	No
MOLECULAR PROFILING INSTITUTE	TRENT & VON HOFF/BD MEM	128,044	MGMT AND OTHER SERVICES		No
PINNACLE WEST CAPITAL	WILLIAM POST/CEO	144,538	INVESTMENT SERVICES		No

efile GRAPHIC print - DO NOT PROCESS	As Filed Data -	DLN: 93493137026420

SCHEDULE O (Form 990)

Department of the Treasury
Internal Revenue Service

Supplemental Information to Form 990

▶ Attach to Form 990. To be completed by organizations to provide additional information for responses to specific questions for the Form 990 or to provide any additional information.

OMB No 1545-0047

2008

Open to Public Inspection

Name of the organization	Employer identification number
THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE	75-3065445

Identifier	Return Reference	Explanation
ORGANIZATION'S MISSION STATEMENT	FORM 990, PART I, LINE 1, AND PART III, LINE 1	THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN) IS A NONPROFIT BIOMEDICAL RESEARCH INSTITUTE FOCUSED ON DEVELOPING EARLIER DIAGNOSTICS AND SMARTER TREATMENTS BY EMPLOYING INNOVATIVE ADVANCES ARISING FROM THE HUMAN GENOME PROJECT AND APPLYING THEM TO THE DEVELOPMENT OF DIAGNOSTICS, PROGNOSTICS AND THERAPIES FOR CANCER, NEUROLOGICAL DISORDERS, DIABETES AND OTHER COMPLEX DISEASES

Identifier	Return Reference	Explanation
DESCRIPTION OF PROGRAM SERVICE ACCOMPLISHMENTS	FORM 990, PART III, LINES 4A - 4C	LINE 4A - PROGRAM SERVICE ACTIVITY #1 TGEN'S NEUROGENOMICS DIVISION, IN CONJUNCTION WITH OTHER LEADERS IN ALZHEIMER'S DISEASE (AD) GENETICS RESEARCH, HAS UNDERTAKEN A LARGE COLLABORATIVE EFFORT TO IDENTIFY EVERY GENETIC VARIATION THAT RESULTS IN INCREASED RISK FOR ALZHEIMER'S DISEASE BY SCANNING THE GENOME OF THOUSANDS OF INDIVIDUALS BOTH WITH AND WITHOUT AD, WE WILL IDENTIFY THE GENETIC VARIANTS THAT CONTRIBUTE A SIGNIFICANT INCREASED RISK FOR DEVELOPING AD THESE GENETIC VARIANTS CAN BE USED BOTH TO PROVIDE NEW INFORMATION ABOUT THE CAUSES OF AD AND AS A DIAGNOSTIC TOOL TO DETERMINE AN INDIVIDUAL'S INNATE GENETIC RISK FOR THE DISORDER LINE 4B - PROGRAM SERVICE ACTIVITY #2 TGEN'S GENOTYPING TECHNOLOGY CENTER ANALYZES BITS OF DNA CALLED SINGLE NUCLEOTIDE POLYMORPHISMS (SNPS) WHICH GIVE RESEARCHERS THE POWER TO IDENTIFY DISEASE-CAUSING GENES, ASSOCIATIONS, AND DNA SIGNATURES, ALL OF WHICH HAVE PROFOUND IMPLICATIONS FOR DETECTION, PROGNOSIS AND THERAPEUTIC INTERVENTION THE SNP GENOTYPING CENTER OFFERS INNOVATIVE SOLUTIONS THAT ADDRESS THE REQUIREMENTS FOR FLEXIBILITY, SIMPLICITY, THROUGHPUT, ECONOMY, AND ACCURACY LINE 4C - PROGRAM SERVICE ACTIVITY #3 THE PHARMACEUTICAL GENOMICS DIVISION IS DEDICATED TO ACCELERATING THE DRUG DISCOVERY PROCESS BY DEVELOPING NEW TECHNOLOGIES AND INTEGRATED SYSTEMS BIOLOGY APPROACHES IN ORDER TO TRANSLATE GENOMIC DATA RAPIDLY TO NEW ANTI-CANCER DRUG COMPOUNDS THE PURPOSE OF THE LAB IS TO DEVELOP AND DISCOVER SMALL MOLECULE, ANTIBODY, AND NUCLEIC ACID BASED AGENTS TO TARGET THE MOST PROMISING GENE AND GENE PRODUCTS FOR ADVANCEMENT TO PRECLINICAL AND CLINICAL TESTING THIS RESEARCH IS SETTING THE STAGE FOR THE ABILITY TO RAPIDLY AND EFFECTIVELY TRANSLATE GENOMICS INTO ADVANCES IN ANTI-CANCER DRUG DEVELOPMENT

Identifier	Return Reference	Explanation
PROGRAM SERVICE ACCOMPLISHMENTS (CONTINUED)	FORM 990, PART III, LINE 4	Introduction This report highlights TGen's capacity to impact a broad spectrum of diseases -locally and globally- and serves as an overview of activities across all areas of TGen In that respect, FY 09 proved to be a productive year Through TGen's sustained effort toward structuring the institute's scientific focus and vision around a collaborative model, we continued to fare well despite the challenges presented by a down economy The strength of our scientific programs enabled us to pursue a number of significant opportunities over the past year, by building on both established and new relationships Notable research achievements include results from a genome-wide scan that offers new insight into the etiology of melanoma and how under-expression of genes and metabolic deficits play a role in the development and progression of individuals with Alzheimer's disease Clinically, we report here the results of two trials presented at the Annual Meeting of the American Association of Cancer Research held in April, both stemming from work at TGen Clinical Research Services (TCRS) at Scottsdale Healthcare With 25 active clinical trials for advanced and or rare cancers, TCRS is now one of the leading centers for Phase I oncology trials in the nation In research related news, our strategic alliances with Mayo Clinic and Scottsdale Healthcare focused on developing improved therapeutics to fight cancer, while our work with Arizona State University expanded our abilities in the area of supercomputing Additionally, we continue to dialogue with the Van Andel Institute in Grand Rapids, Michigan, regarding a strategic alliance and affiliation In terms of commercialization and company formation, TGen spun off two companies MedTrust Online, a reliable one-stop medical information source for oncologists, and Catapult Bio, a non-profit group designed to help transform emerging research discoveries into business opportunities A third company, Casework Genetics, utilizes, through a licensing agreement, a process stemming from Associate Investigator Dr David Craig and colleagues' published report in PLoS Genetics that proved possible the use of bioinformatics to detect a single individual's SNP profile in publicly available aggregate datasets Once again, TGen researchers made a number of research discoveries, the results of which appeared in leading peer-reviewed scientific journals Additionally, a description of grant, contract, philanthropic, educational and media activity follows Peer-Reviewed Laboratory Research/Publications The increased understanding of molecular medicine is shifting clinical practice from treatment based on symptoms to treatment based on the underlying causes of disease At TGen, our faculty work to discover the underlying cause of disease progression and resistance to therapy and why some individuals encounter debilitating diseases and others live healthy lives Although all the puzzle pieces of our genetic make-up have been identified, scientists and clinicians now have the formidable task of interpreting how they fit together in order to apply the genome map to patient care The fusion of modern medicine with the power of translational research fuels the next wave of treatments for disease Areas of research fall into three broad categories - Oncology (melanoma, breast, prostate, ovarian, lung cancers, etc), Metabolic (diabetes and heart disease) and Neurological (autism, Alzheimer's, ALS, and other brain-related diseases) - all of which impact Arizonans at alarming rates The research results appear in a number of scientific and medical journals and add to the growing knowledge base of molecular research and medicine To further accelerate the pace of research and strengthen further the translational aspects of TGen's work, in early February, TGen announced the framework for a strategic alliance and affiliation agreement with the Van Andel Research Institute (VARI) in Grand Rapids, Michigan, that will enable both institutes to maximize their worldwide contributions to science and health The agreement will enable both institutes to speed up their mutual goals of moving research discoveries about cancer and other debilitating medical conditions as quickly as possible from laboratories to patient care The alliance combines the groundbreaking basic research expertise of VARI with the cutting-edge translational genomics and analysis of TGen In FY09, TGen researchers published numerous scholarly articles in peer-reviewed academic journals These include publication in leading scientific journals such as Science, Nature, Nature Genetics, Genomics, Cancer Research, and a host of other disease-associated publications (e g Diabetes, Molecular Cancer Therapeutics, etc) Select Highlights for FY09 include July 2008 TGen Associate Investigator Dr David Craig and colleagues published a report in PLoS Genetics that proved possible the use of bioinformatics to detect a single individual's SNP profile in publicly available aggregate datasets - something that was thought to be impossible prior to the TGen study The finding also has forensic implications in that it is now possible to confirm the presence of an individual at a crime scene, even when that person leaves only a trace of DNA, and even when it is within a DNA pool of hundreds, if not thousands, of other individuals Citation Homer N, Szelinger S, Redman M, Duggan D, Tembe W, et al (2008) Resolving Individuals Contributing Trace Amounts of DNA to Highly Complex Mixtures Using High-Density SNP Genotyping Microarrays PLoS Genet 4(8) e1000167 doi 10 1371/journal pgen 1000167 August 2008 In a study published as a "priority report" paper in Cancer Research, Dr Pamela Pollock, an associate investigator in TGen's Cancer and Cell Biology Division, led a study that identified a way to not only stop the growth of, but also kill, certain kinds of uterine cancer cells By introducing a commercially available inhibitor drug, the researchers showed they could affect receptors that get stuck in the "on" position and signal the endometrial cells to grow out of control This work was done in association with Dr Paul Goodfellow, an expert in endometrial cancer and a professor in the departments of Surgery and of Obstetrics and Gynecology at Washington University Clinical trials are planned within a year Citation Inhibition of Activated Fibroblast Growth Factor Receptor 2 in Endometrial Cancer Cells Induces Cell Death Despite PTEN Abrogation Sara A Byron, Michael G Gartside, Candice L Wellens, Mary A Mallon, Jack B Keenan, Matthew A Powell, Paul J Goodfellow, and Pamela M Pollock Cancer Res 2008 68 6902-6907 doi 10 1158/0008-5472 CAN-08-0770 September 2008 Dr Craig and colleagues published a paper in Nature Methods about how TGen discovered a faster and less expensive way for scientists to find which genes might affect human health Using bar-codes, not unlike what shoppers find in grocery stores, TGen researchers found a way to index portions of the nearly 3-billion-base human genetic code, making it easier for scientists around the world to zero in on the regions most likely to show variations in genetic traits Initially, this was thought to be of interest to only a select audience Citation Identification of genetic variants using bar-coded multiplexed sequencing Craig DW, Pearson JV, Szelinger S, Sekar A, Redman M, Corneveaux JJ, Pawlowski TL, Laub T, Nunn G, Stephan DA, Homer N, Huentelman MJ Nat Methods 2008 Sep 14 [Epub ahead of print] Work led by Dr Matthew Huentelman, an Associate Investigator in the Neurogenomics Division, and colleagues led to a published report in Neurobiology of Aging that showed a link between a certain flavor of the KIBRA protein and Alzheimer's disease The study built on a groundbreaking discovery made by TGen two years ago and published in Science that linked KIBRA and memory in healthy adults In this most recent study, TGen collaborated with universities and research institutions across Arizona, the nation and Europe This new research could lead to techniques that might prevent, detect and treat Alzheimer's, and even enhance memory Citation Evidence for an association between KIBRA and late-onset Alzheimer's disease Corneveaux JJ, Liang WS, Reiman EM, Webster JA, Myers AJ, Zismann VL, Joshipura KD, Pearson JV, Hu-Lince D, Craig DW, Coon KD, Dunckley T, Bandy D, Lee W, Chen K, Beach TG, Mastroeni D, Grover A, Ravid R, Sando SB, Aasly JO, Heun R, Jessen F, Kisch H, Rogers

Identifier	Return Reference	Explanation
PROGRAM SERVICE ACCOMPLISHMENTS (CONTINUED)	FORM 990, PART III, LINE 4	J, Hutton ML, Melquist S, Petersen RC, Alexander GE, Caselli RJ, Papassotiropoulos A, Stephan DA, Huentelman MJ Neurobiol Aging 2008 Sep 11 [Epub ahead of print] December 2008 Research led by Dr Matthew Huentelman, a recently promoted Investigator in the Neurogenomics Division, reported in the December edition of Human Molecular Genetics about the identification of a gene that could help explain why some people lose their hearing as they age Citation GRM7 Variants Confer Susceptibility To Age-Related Hearing Impairment Rick A Friedman, Lut Van Laer, Matthew J Huentelman, Sonal S Sheth, Els Van Eyken, Jason J Corneveaux, Waibhav D Tembe, Rebecca F Halperin, Ashley Q Thorburn, Sofie Thys, Sarah Bonneux, Erik Fransen, Jeroen Huyghe, Ilmari Pyykk, Cor W R J Cremers, Hannie Kremer, Ingeborg Dhooge, Dafydd Stephens, Eva Orzan, Markus Pfister, Michael Bille, Agnete Parving, Martti Sorri, Paul H Van de Heyning, Linna Makmura, Jeffrey D Ohmen, Frederick H Linthicum, Jr , Jose N Fayad, John V Pearson, David W Craig, Dietrich A Stephan, and Guy Van Camp Hum Mol Genet 2009 Feb 15,18(4) 785-96 Epub 2008 Dec 1 January 2009 A cover story in Molecular Cancer Research highlighted the continuing work of Dr Pamela Pollock, researcher Michael Gartside and other TGen scientists and collaborators into the causes of melanoma The published results revealed a gene that mutates in different ways in different kinds of cancer This work began more than six years ago in Dr Jeffrey Trent's lab at the National Institutes of Health Citation Loss-Of-Function FGFR2 Mutations In Melanoma Michael G Gartside, Huaibin Chen, Omar A Ibrahimi, Sara A Byron, Amy V Curtis, Candice L Wellens, Ana Bengston, Laura M Yudt, Anna V Eliseenkova, Jinghong Ma, John A Curtin, Pilar Hyder, Ursula L Harper, Erica Riedesel, Graham J Mann, Jeffrey M Trent, Boris C Bastian, Paul S Meltzer, Moosa Mohammadi, Pamela M Pollock Molecular Cancer Research 7, 41-54, January 1, 2009 doi 10 1158/1541-7786 MCR-08-0021 February 2009 A new study released February 2 by TGen's Dr Matthew Huentelman and colleagues at Arizona State University in the journal Behavioral Neuroscience, show that hydroxyfasudil, the active form of the parent drug Fasudil, improved spatial learning and working memory in middle-aged rats when negotiating a complicated maze The findings suggest that hydroxyfasudil may influence similar cognitive processes in humans involving the hippocampus, a part of the brain that has been shown to deteriorate in patients with age-related disorders Fasudil has been used for more than 10 years to help protect the brain in stroke patients by dilating blood vessels when blood flow is curtailed Citation Peripheral Delivery of a ROCK Inhibitor Improves Learning and Working Memory Matthew J Huentelman, Dietrich A Stephan, Joshua Talboom, Jason J Corneveaux, David M Reiman, Jill D Gerber, Carol A Barnes, Gene E Alexander, Eric M Reiman, and Heather A Bimonte-Nelson Behavioral Neuroscience, 2009, Vol 123, No 1, 218-223 April 2009 A study by Dr Michael Berens, Director of TGen's Cancer and Cell Biology Division, in association with Barrow's Neurological Institute, found that a gene called NHERF-1 plays a significant role in malignant brain tumors known as glioblastoma multiforme, or GBM NHERF-1 may be a serious target for drugs that could prevent malignant tumors from rapidly multiplying and invading other parts of the brain, according to the study, which appeared as a cover story in April's edition of Neoplasia, an international journal of cancer research Citation NHERF-1 Modulator of Glioblastoma Cell Migration and Invasion Kerri L Kislin, Wendy S McDonough, Brock A Armstrong and Michael E Berens of TGen's Cancer and Cell Biology Division, and Jennifer M Eschbacher of the Department of Pathology, St Joseph's Hospital and Medical Center Cover story in Neoplasia, April 2009, 11, 377-387 Clinical Research Established in 2006, TGen Clinical Research Services, a strategic alliance with Scottsdale Healthcare (SHC), provides a direct clinical research site for TGen TCRS brings new clinical research into the community, to those patients who would otherwise have to travel someplace else for access to new therapies or prevention agents Dr Daniel Von Hoff, TGen's Physician-in-Chief, serves as TCRS Chief Scientific Officer TCRS clinicians focus on clinical trials with targeted agents and genomics-based individualized therapy TCRS, with an initial focus on cancer, allows the unique opportunity for TGen to transition its laboratory-based research to patient care centered on individualized therapy TCRS works in collaboration with physicians in the local Arizona community and across the U S to provide options for the care of their patients TCRS serves as an international referral center for patients from anywhere in the world Every patient with a physician referral is welcome, provided they meet the requirements In some cases, the patient may be evaluated through the new clinic, but receive treatment from their referring physician We work flexibly to ensure the best and most complete care for patients Additionally, TCRS enthusiastically works in collaboration with other clinical trial sites throughout the U S who share TGen's ideas and passion for achieving results quickly, including current collaborators (Mayo Clinic, U S Oncology, M D Anderson Cancer Center, the Arizona Cancer Center, and others) who wish to participate TCRS will not establish exclusive relationships that preclude others from participating With 25 active clinical trials for advanced and/or rare cancers, TCRS is one of the leading centers for Phase I oncology trials in the nation These clinical trials give options that did not exist before to Phoenix-area patients as well as patients from all over the country TCRS is conducting clinical trials across a number of cancer types Further development of cancer specific divisions in pancreatic cancer, breast cancer, leukemia, prostate cancer, lung cancer, and melanoma are under development Patient participation in clinical trials is a necessary component to the research process According to the National Institutes for Health, only 3% of adults with cancer are participating in clinical trials At TCRS, the clinical trial participation rate is a remarkable 60% Interestingly, a recent study shows that if given the opportunity and access to clinical trials, 63% of the population would participate, according to a survey by the Charlton Research Co Patient participation in clinical trials at TCRS includes - 125 visits per month - 35-45 new patients per month - 400-600 patient samples collected per month Grant Support Grant funding is often the lifeblood of research In FY09, TGen investigators submitted 210 grants, totaling $158,050,724 - a 65 percent increase over FY08 in terms of submission, and an 82 percent increase in

Identifier	Return Reference	Explanation
PROGRAM SERVICE ACCOMPLISHMENTS (CONTINUED)	FORM 990, PART III, LINE 4	terms of total dollar value TGen was awarded 14 grants, totaling $1,207,081, with an additional 135 grants pending and in reviews totaling $125,806,587 Additionally, TGen received $17,722,428 from FY08 pending grants, bringing the awarded total for FY09 to $18,929,509 TGen's success rate currently rests at 27 percent of total grants submitted, placing the Institute nearly eight percent higher than the national average Highlights include 1 In May, the national Stand Up to Cancer initiative awarded a total of $74 million for five major cancer research projects The TGen/University of Pennsylvania proposal to launch new techniques in the fight against pancreatic cancer received the largest amount $18 million TGen Physician-In-Chief Dr Daniel Von Hoff will co-direct the project 2 The National Institutes of Health (NIH) through its National Center for Research Resources awarded a one-year grant, totaling $1,996,810, to Dr Ed Suh, a senior investigator and TGen's Chief Information Officer, that will allow TGen to work with Arizona State University in doubling our supercomputing capabilities 3 NIH's National Cancer Institute awarded a five-year subcontracted grant, totaling $937,206, to Dr Kevin Brown, an associate investigator in TGen's Integrated Cancer Genomics Division He is looking for mutations in genes that predispose people to pancreatic cancer 4 NIH's National Institute of Allergy and Infectious Diseases awarded a four-year subcontracted grant, totaling $674,304, to Dr Paul Keim, director of TGen's Pathogen Genomics Division Keim is conducting a three-part study -- involving flu clones and drug resistance, optimal dosages of drugs to suppress viruses and minimize drug resistance, and optimizing drug combinations - aimed at helping avoid a flu pandemic 5 NIH's National Cancer Institute awarded a nearly four-year subcontracted grant, totaling $615,824, to TGen, which is assisting Wake Forest University's School of Medicine in Winston-Salem, N C , with genomic analysis in the study of prostate cancer Understanding genetic variations could lead to the identification of risk factors that could then be used to prevent, diagnose and treat this disease Dr John Carpten, senior investigator and director of TGen's Integrated Cancer Genomics Division, is working on this project with Dr David Duggan, an investigator in the Genetic Basis of Human Disease Division and director of TGen's Genotyping Technology Center 6 The American Association for Cancer Research awarded a three-year grant, totaling $180,000, to Dr Timothy Whitsett, a post-doctorate fellow who is working with Dr Suwon Kim, a TGen cancer investigator and an assistant professor of Biomedical Sciences at the University of Arizona Medical School - Phoenix - in partnership with Arizona State University They are looking into the effects of a tumor-suppressor gene known as ING4 in their quest to prevent and treat breast cancer 7 The Arizona Biomedical Research Commission awarded a two-year grant, totaling $100,000, to Dr Raoul Tibes, an associate investigator for TGen's Clinical Research Services at Scottsdale Healthcare Shea He is conducting genomic screening to help guide new studies and discover drugs and other agents that could help treat Acute Myeloid Leukemia 8 The National Science Foundation has awarded a four-year grant, totaling $300,000, to Dr Zoe Lacroix, a TGen computer scientist, who is working on computing capabilities critical to the development of systems that would enable patients to help manage their own healthcare over the Internet The goal also is to help develop a network of computational tools, software systems and genomic technologies critical to drug discovery and development and to healthcare decision support systems 9 The Arizona Alzheimer's Research Center has awarded four, four-year grants, totaling $295,922, to Dr Matthew Huentelman, an Investigator in TGen's Neurogenomics Division, to fund genotyping, identification of regions of the genome associated with Alzheimer's disease risk, the use of multiple technologies to study pathological processes in Alzheimer's disease, and assess Alzheimer's disease genetic associations 10 The Arizona Alzheimer's Research Center awarded a four-year grant, totaling $25,000, to Jill Peters, TGen's Director of Legislative Affairs and Community Outreach The grant will enable her to serve as part of the Alzheimer's disease consortium's education and community outreach efforts with Arizona's Native American communities 11 The Arizona Biomedical Research Commission awarded a three-year grant, totaling $75,000, to Dr Nhan Tran, an Associate Investigator in TGen's Tumor Research Lab He is working on more effective ways to treat lung cancer by banking lung tumor tissue samples 12 The National Institutes of Health's National Cancer Institute has awarded a 5-year grant, totaling $439,237, to Dr Spyro Mousses, Director of TGen's Pharmaceutical Genomics Division, who is working on a genome-wide RNAi vulnerability map for myeloma In association with Mayo Clinic, the goal is to identify candidate genes in myeloma growth and determine the extent to which they can be used as biomarkers for therapies 13 Four grants to Dr David Duggan, an Investigator in TGen's Genetic Basis of Human Disease Division a $2 4 million over four years from the NIH to work with Seattle's Fred Hutchinson Cancer Research Center for the Women's Health Initiative, which will involve the genotyping of 72,000 participants for about 50 putative disease-specific genetic variants and 50 inherited genetic markers b $401,922 over two years from the NIH to work with the Fred Hutchinson center to investigate the role of genetic variability and biomarkers in two specific pathways associated with colorectal cancer study c $1 4 million over four years from the NIH to work with the University of Hawaii to investigate the role of inflammation and innate immunity in cancer, especially colorectal cancer d $353,384 from NIH to work with the Fred Hutchinson center on a yearlong genome-wide association study of non-synonymous single-nucleotide polymorphism in colon cancer Enterprise Efforts and Collaboration The offices of Business Development and Technology Transfer work to develop an appropriate administrative structure to handle commercialization of its intellectual property, as well as developing effective ways to partner with the commercial sector This takes the form of the establishment of cooperative research agreements with industry and licensing of TGen technology and discoveries Further, it allows TGen to form a commercial subsidiary

Identifier	Return Reference	Explanation
PROGRAM SERVICE ACCOMPLISHMENTS (CONTINUED)	FORM 990, PART III, LINE 4	This "enterprise effort" may form various operating subsidiaries to pursue specific joint venture projects TGen's commercial subsidiary w ill be able to accept investments, joint ventures, exclusive arrangements, and the full range of creative mechanisms for commercialization It is intended that dividends, gains, or profits, w hich are remitted to TGen w ill be used to provide general support for its research efforts Invention Disclosures Invention Disclosures are filed through TGen's Office of Technology Transfer (OTT) as the first step tow ard a possible patent application or other appropriate form of intellectual property protection TGen filed 48 invention disclosures in FY09 based on discoveries stemming from TGen-led research Commercialization / Spin Offs In terms of commercialization and company formation, TGen spun off tw o companies in FY09 MedTrust Online, a reliable one-stop medical information source for oncologists, and Catapult Bio, a non-profit group designed to help transform emerging research discoveries into business opportunities A third company, Casew ork Genetics, utilizes, through a licensing agreement, a process stemming from Associate Investigator Dr David Craig and colleagues' published report in PLoS Genetics that proved possible the use of bioinformatics to detect a single individual's SNP profile in publicly available aggregate datasets Contracts and Collaborations TGen signed a total of 374 contracts in FY09 (a 31 percent increase over FY08), broken dow n as follow s 1 TGen signed 101 confidential disclosure agreements (CDA) in FY09 CDAs create a confidential relationship betw een TGen and a host of potential collaborators/partners While not all CDAs result in a formal collaboration or partnership, they do provide a number of institutes and companies (locally, nationally and internationally) a greater picture of TGen's capabilities and reflect positively as a w hole on Arizona's biomedical science pursuits 2 TGen signed 70 material transfer agreements (MTA) in FY08 MTAs form the backbone of numerous TGen research collaborations as shared materials include reagents, cell lines, softw are and more 3 TGen signed 55 Research Collaborations (many w ith local and state affiliations) in FY09, including agreements that further research into a host of diseases, including brain cancer, melanoma, Alzheimer's and autism 4 Additionally, TGen signed 24 consulting agreements, 50 professional services agreements, 17 master service agreements, and 57 agreements covering miscellaneous activities such as memorandums of understanding, leases, and evaluation agreements Select highlights for FY09 include 1 In one of the most significant moves, TGen entered into a Master Grant Agreement w ith the Ben & Catherine Ivy Foundation, and agreed to lead a consortium of eight institutions throughout the United States to conduct the Ivy Genomics-Based Medicine Project (GBM) The GBM Project, headed by Dr Jeffrey Trent, Scientific Director, and Dr Michael Berens, Principal Investigator, represents a tw o-stage program that w ill study human glioblastoma and use profiles obtained to guide therapy planning in patients w ith recurring glioblastoma All eight consortium members signed Research Collaboration Contracts in June and July Mayo Clinic Rochester, Van Andel Research Institute, Case Western Reserve University School of Medicine, The Ohio State University Research Foundation, Henry Ford Health System, University of Alabama at Birmingham, M D Anderson Cancer Center, and the University of California San Francisco 2 In February, TGen entered into a strategic alliance w ith Mayo Clinic's NCI-designated Comprehensive Cancer Center, a move expected to result in further collaborations in cancer research Specifically, a number of TGen researchers w ill become members in the Mayo Clinic Cancer Center Their membership w ill facilitate and enhance collaboration among the faculty of both organizations on cancer research initiatives Such collaboration w ill allow for greater access to resources and expertise in areas of mutual scientific interest 3 An amendment to the Eli Lilly agreement that increases the budget an additional $145,763 for human glioma xenografts study conducted by Dr Michael Berens 4 An amendment to a Banner Health research plan signed in April extends the term of "EGFR Characterization of Colorectal Cancer" through December 31, 2010 5 An agreement w ith John C Lincoln Hospital provides for a collaboration w ith an initial focus on obtaining breast tissue samples from possible breast cancers for TGen's research bank 6 An agreement w ith Catholic Healthcare West provides for collection of brain tumor samples in paraffin DNA pilot - Phase 1 7 New York University School of Medicine Initial projects entitled "Compound Screening in a Mutationally Characterized Melanoma Cell Line Panel" and "Genetic Analysis of FGFR2 in Primary Melanomas" 8 Texas A & M Agreement governing intellectual property rights and licensing for development, marketing and sale 9 GE Healthcare UK Consultation and Critical Biological Evaluation of the Platform (Microarray Device) Performance 10 University of Arizona Research Plan for "Compound Screening in a Mutationally Characterized Melanoma Cell Line Panel" (research by Drs Pam Pollock and Laurence Hurley) 11 Scottsdale Healthcare Amendments 3, 4 & 5 to Research Operating Agreement - To extend term of agreement through negotiation process for amended agreement 12 Maricopa Integrated Health System Research Plan - "Characterization of Resistant Biomarkers to Standard Anti-Cancer Drugs Prior to Treatment of Ovarian Cancer" (research by Drs Cunliffe & Greenspan) 13 Children's Hospital of Los Angeles RCA - Applying TGen's expertise in high definition genomics to the study of AT/RT and brain stem glioma pediatric tumors (research by Drs Barrett & Epstein) 14 Banner Health-Johnnie B Byrd Sr Alzheimer's Center & Research Institute RCA - Study of late onset Alzheimer's Disease in connection w ith Kronos Science Laboratories (research by Drs Huentelman, Reiman & Myers)

Identifier	Return Reference	Explanation
PROGRAM SERVICE ACCOMPLISHMENTS (CONTINUED)	FORM 990, PART III, LINE 4	15 Washington University RCA - Initial focus to be expanding upon and validating known information about genes associated with various stages of endometrial cancer to potentially develop a prognostic and/or therapeutic (research by Drs Pollock & Goodfellow) 16 GlaxoSmithKline Master Research Services Agreement & Statement of Work - "Cellular Genomic LKB1 Synthetic Lethal Screen" (research by Dr Holly Yin) 17 Oregon Health & Science University RCA - "RNAi Screen for Therapeutic Target Identification in Primary Acute Myeloid Leukemia Cells" (research by Drs Tibes & Loriaux) Job Creation 38 new full-time equivalent positions were created in FY09 with salaries and benefits totaling approximately $2,638,000 Salaries for temporary positions (those positions created for a finite period of time) totaled $350,000 and student salaries were just over $300,000, bringing the overall total to $3,288,000 TGen full-time employees now total 287, with 83 percent holding a college degree (46 percent of whom hold advanced degrees) Positions filled include Accountant I Accountant II Administrative Assistant Animal Technician Biosafety Compliance Specialist Business Analyst Database Analyst Director, Business Development Financial Analyst II Flow Cytometry Operator Grants Specialist Graphic Designer Jr Project Manager Payroll Manager Post-Doc Fellow Programmer II Project Manager Proteomics Lab Head Purchasing Assistant Research Associate Research Associate II Research Associate III Sr Research Associate Sr Software Engineer We have stressed in the past that internships serve as a pipeline to TGen in terms of future recruitment, and supporting the statewide initiative towards education and development for the students in the life sciences Additionally, TGen is a proving ground where talented undergraduates gain valuable experience prior to returning to earn advanced degrees at one of the state's three universities TGen had three such candidates in FY09 Education and Public Outreach TGen, through its education and outreach programs, seeks to increase the working knowledge of genomics within the community at large and to help educate, train, and excite the next generation of students pursuing education and careers in science, technology, engineering and mathematics (STEM) TGen is proud to be a community partner in education and has committed resources and expertise to improve the quality of science education in Arizona TGen aims to strategically collaborate with academic institutions at all levels within Arizona to capitalize on existing programs and enhance STEM initiatives while avoiding duplication of efforts To this end, TGen has been successful in building a pipeline of programs, activities and outreach targeted to the entire P-20 spectrum and beyond The major programmatic focus of TGen's education efforts centers on the Helios Scholars Program at TGen, an annual summer internship program that pairs a student with a TGen scientist/mentor that provides hands-on laboratory training TGen also offers an Academic Year Internship Program, which provides a limited number of volunteer internship positions that are available during the academic year, based on the needs and projected workload of the host laboratory In FYO9, TGen trained 66 high school, undergraduate, and graduate interns Arizona students comprised 100 percent of the interns, with 71 percent attending academic institutions within the state 16 percent were graduate/medical students, 60 percent undergraduate students, and 24 percent high school students Teacher Training Programs In FY09, TGen completed a three-year grant funded by the Arizona Board of Regents (ABOR) in partnership with NAU that provided biotech programming for Arizona's top high school science teachers Teachers gained new content knowledge, became aware of rapid advances in biotechnology, current and future uses of biotechnology, and learned hands-on laboratory skills Most importantly, teachers learned how to transfer the content learned into curriculum and activities for their classrooms As part of the final phase of the program, teachers learned how to research, write and successfully compete for grants for their classrooms TGen also received (2009-2012) a new subcontract with NAU - a 3-year GK-12 National Science Foundation (NSF) grant providing content for teachers paired with graduate student mentors As part of this grant, TGen will provide summer workshops in genomics for the teachers and graduate students Educational and Public Tours TGen values the opportunity to share its state-of-the-art research facility with the community through public tours of TGen Tour participants walk through working laboratories, where they may observe scientists researching the latest detection and treatment procedures for cancer, diabetes and neurological diseases The community's interest in tours continues to grow In FY09, TGen hosted tours for a diverse range of community members and organizations Tour requests may be submitted via the website at http //www tgen org/education/tour_request cfm Stimulating growth of Arizona's life science industries An important factor in continuing TGen's success is communication with various stakeholders and the broader Arizona community Toward that goal, TGen Sr leadership participates in a myriad of community-related activities through presentations at regional meetings and as a member or participant of various committees and groups The following is a list of selected Committee/Board appointments of TGen leadership 1 Arizona Alzheimer's Consortium Board 2 Arizona Bioscience Roadmap Steering Committee, Flinn Foundation 3 Arizona Commission on Medical Education and Research, Governor's Council 4 Arizona Skill Standards Commission 5 Arizona Technology Council 6 Chair, Executive Committee, Clinical Translational Service Award (CTSA) 7 Downtown Phoenix Partnership 8 Governor's Council on Innovation and Technology 9 Greater Phoenix Leadership 10 Greater Phoenix Economic Council 11 Phoenix Community Alliance 12 Maricopa Partnership Arts and Culture 13 Third Personalized Medical Science and Technology Initiative, Virginia Piper Media and Interactive TGen remains active in pursing positive media exposure for the institute's research activities Media exposure raises awareness and brings added credibility to the Institute and the state In total, TGen received greater than 900 media mentions in FY09 in various trade and public media locally, nationally and internationally While highlighting TGen specifically, these stories also build a greater presence for the continuously expanding biomedical science initiatives occurring in Arizona Media outlets include Arizona Daily Star Arizona Daily Sun Arizona Republic Associated Press BioInform Canberra Times (Australia) Conde Nast Portfolio East Valley Tribune GenomeWeb Grand Rapids Press KJZZ KPHO KPNX KTKV Los Angeles Times The Philadelphia Inquirer Phoenix Business Journal Prensa Latina in Cuba Science Daily Times (UK) Tucson Citizen United Press International On-line To better highlight all areas of TGen research and clinical areas, and further enhance TGen's public face, TGen's redesigned web site, www tgen org, launched in September 2008 The new site is optimized for search engines and features an expanded homepage navigation layout that enables visitors to connect to the site's most visited areas with one click The open design makes it easier to read The addition of a 'lightbox' viewer enables the display of high-resolution images without the visitor leaving the page It features a simplified integration of multimedia content

Identifier	Return Reference	Explanation
BUSINESS AND FAMILY RELATIONSHIPS	FORM 990, PART VI, LINE 2	RICHARD BOALS, ROBERT BULLA AND WILLIAM POST HAVE A BUSINESS RELATIONSHIP MICHAEL BITTNER AND EDWARD SUH HAVE A BUSINESS RELATIONSHIP DANIEL VON HOFF AND MICHAEL BITTNER HAVE A BUSINESS RELATIONSHIP JEFFREY TRENT, DANIEL VON HOFF AND EDWARD SUH HAVE A BUSINESS RELATIONSHIP

Identifier	Return Reference	Explanation
PROCESS USED BY MANAGEMENT AND/OR GOVERNING BODY TO REVIEW 990	FORM 990, PART VI, LINE 10	THE FORM 990 IS PREPARED BY AN OUTSIDE ACCOUNTING FIRM BASED ON INFORMATION PROVIDED BY THE FINANCE DEPARTMENT THE 990 IS THEN REVIEWED BY MANAGEMENT IN THE FINANCE DEPARTMENT AND POSTED ON THE BOARD WEBSITE FOR REVIEW PRIOR TO FILING WITH THE IRS

Identifier	Return Reference	Explanation
PROCESS USED TO MONITOR TRANSACTIONS FOR CONFLICTS OF INTEREST	FORM 990, PART VI, LINE 12C	TGen issues a conflict of interest questionnaire on an annual basis to all Director level positions and above in addition to any key employees designated by the Chief Operating Officer The questionnaires are reviewed by the Chief Financial Officer and those employees with conflicts are sent for further review to Chief Operating Officer to ensure a plan is set forth Updates to the list are handled on an as needed basis based on contract reviews and employee information

Identifier	Return Reference	Explanation
PROCESS USED TO DETERMINE COMPENSATION	FORM 990, PART VI, LINES 15A AND 15B	TGen's Governance and Executive Compensation Committee will act in an "advice and consent" capacity reviewing the recommendations for the President and Scientific Director regarding the compensation of disqualified person and forwarding final recommendations to the full Board for approval Disqualified persons (except for the President and Scientific Director) will not be present for, or participate in, Committee deliberations concerning their compensation (other than to answer questions) The President and Scientific Director will participate in the deliberations concerning the compensation of direct reports During the decision making process, the Committee will adhere to the Executive Compensation philosophy The Committee is authorized (and provided with sufficient funding) to annually engage outside independent compensation and legal advisors, when deemed necessary and advisable The Committee will comply with the "Rebuttable Presumption of Reasonableness" under Section 4958 of the Internal Revenue Code whenever possible The Committee will review and understand the Internal Revenue Code provisions dealing with "excess benefit transactions concerning Disqualified Persons' compensation" When developing a compensation philosophy TGen kept in mind the following factors The TGen mission and strategy The TGen culture Trends in compensation in the external environment Trends in recruitment of new employees Trends in organizational employee turnover TGen's life cycle stage

Identifier	Return Reference	Explanation
AVAILABILITY OF GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY,	AND FINANCIAL STATEMENTS TO THE GENERAL PUBLIC	FORM 990, PART VI, LINE 19 THE ORGANIZATION'S GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE PROVIDED TO THE GENERAL PUBLIC UPON REQUEST

Identifier	Return Reference	Explanation
CONSOLIDATED AUDITED FINANCIAL STATEMENTS	FORM 990, PART XI, LINE 2	THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE IS PART OF CONSOLIDATED AUDITED FINANCIAL STATEMENTS NO STAND-ALONE AUDIT FOR TGEN IS PERFORMED THEREFORE THIS QUESTION IS ANSWERED NO IN ACCORDANCE WITH THE INSTRUCTIONS

SCHEDULE R (Form 990)

Department of the Treasury
Internal Revenue Service

Related Organizations and Unrelated Partnerships

▶ Attach to Form 990. To be completed by organizations that answered "Yes" to Form 990, Part IV, lines 33, 34, 35, 36, or 37.
▶ See separate instructions.

OMB No 1545-0047

2008

Open to Public Inspection

Name of the organization
THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE

Employer identification number
75-3065445

Part I Identification of Disregarded Entities

(A) Name, address, and EIN of disregarded entity	(B) Primary activity	(C) Legal domicile (state or foreign country)	(D) Total income	(E) End-of-year assets	(F) Direct controlling entity
TGEN ACCELERATOR MANAGEMENT LLC 445 NORTH 5TH STREET 600 PHOENIX, AZ 85004 75-3065445	GENOMICS	AZ	0	0	NONE
THE CENTER FOR TRANSLATIONAL DRUG DEV 445 NORTH 5TH STREET 600 PHOENIX, AZ 85004 43-2047329	DRUG DEVEL	AZ	4,038,121	1,815,841	Tgen Acc Mgt

Part II Identification of Related Tax-Exempt Organizations

(A) Name, address, and EIN of related organization	(B) Primary activity	(C) Legal domicile (state or foreign country)	(D) Exempt Code section	(E) Public charity status (if section 501(c)(3))	(F) Direct controlling entity
TGEN RESEARCH INSTITUTE FOUNDATION 400 E VAN BUREN SUITE 850 PHOENIX, AZ85004 33-1092191	FUND RAISING	AZ	501(C)(3)	7	NA

Part III **Identification of Related Organizations Taxable as a Partnership**

(A) Name, address, and EIN of related organization	(B) Primary activity	(C) Legal domicile (state or foreign country)	(D) Direct controlling entity	(E) Predominant income(related, investment, unrelated)	(F) Share of total income	(G) Share of end-of-year assets	(H) Disproprtionate allocations?		(I) Code V—UBI amount on Box 20 of K-1	(J) General or managing partner?	
							Yes	No		Yes	No

Part IV **Identification of Related Organizations Taxable as a Corporation or Trust**

(A) Name, address, and EIN of related organization	(B) Primary activity	(C) Legal domicile (state or foreign country)	(D) Direct controlling entity	(E) Type of entity (C corp, S corp, or trust)	(F) Share of total income	(G) Share of end-of-year assets	(H) Percentage ownership

Part V Transactions with Related Organizations

Note. Complete line 1 if any entity is listed in Parts II, III or IV

			Yes	No
1	During the tax year, did the orgranization engage in any of the following transactions with one or more related organizations listed in Parts II-IV?			
a	Receipt of **(i)** interest **(ii)** annuities **(iii)** royalties **(iv)** rent from a controlled entity	**1a**		**No**
b	Gift, grant, or capital contribution to other organization(s)	**1b**		**No**
c	Gift, grant, or capital contribution from other organization(s)	**1c**	**Yes**	
d	Loans or loan guarantees to or for other organization(s)	**1d**		**No**
e	Loans or loan guarantees by other organization(s)	**1e**		**No**
f	Sale of assets to other organization(s)	**1f**		**No**
g	Purchase of assets from other organization(s)	**1g**		**No**
h	Exchange of assets	**1h**		**No**
i	Lease of facilities, equipment, or other assets to other organization(s)	**1i**		**No**
j	Lease of facilities, equipment, or other assets from other organization(s)	**1j**		**No**
k	Performance of services or membership or fundraising solicitations for other organization(s)	**1k**		**No**
l	Performance of services or membership or fundraising solicitations by other organization(s)	**1l**	**Yes**	
m	Sharing of facilities, equipment, mailing lists, or other assets	**1m**		**No**
n	Sharing of paid employees	**1n**		**No**
o	Reimbursement paid to other organization for expenses	**1o**	**Yes**	
p	Reimbursement paid by other organization for expenses	**1p**		**No**
q	Other transfer of cash or property to other organization(s)	**1q**		**No**
r	Other transfer of cash or property from other organization(s)	**1r**		**No**

2 If the answer to any of the above is "Yes," see the instructions for information on who must complete this line, including covered relationships and transaction thresholds

	(A) Name of other organization(s)	**(B)** Transaction type(a-r)	**(C)** Amount Involved
(1)	TGEN RESEARCH INSTITUTE FOUNDATION	C	4,545,907
(2)	TGEN RESEARCH INSTITUTE FOUNDATION	L	1,012,252
(3)	TGEN RESEARCH INSTITUTE FOUNDATION	O	303,370
(4)			
(5)			
(6)			

Part VI **Unrelated Organizations Taxable as a Partnership**

Provide the following information for each entity taxed as a partnership through which the organization conducted more than five percent of its activities (measured by total assets or gross revenue) that was not a related organization See instructions regarding exclusion for certain investment partnerships

(A) Name, address, and EIN of entity	**(B)** Primary activity	**(C)** Legal domicile (state or foreign country)	**(D)** Are all partners section 501(c)(3) organizations?		**(E)** Share of end-of-year assets	**(F)** Disproprtionate allocations?		**(G)** Code V—UBI amount on Box 20 of K-1	**(H)** General or managing partner?	
			Yes	**No**		**Yes**	**No**		**Yes**	**No**